###begin article-title 0
The chromatin remodeling factor CHD8 interacts with elongating RNA polymerase II and controls expression of the cyclin E2 gene
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 718 723 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 842 850 842 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
CHD8 is a chromatin remodeling ATPase of the SNF2 family. We found that depletion of CHD8 impairs cell proliferation. In order to identify CHD8 target genes, we performed a transcriptomic analysis of CHD8-depleted cells, finding out that CHD8 controls the expression of cyclin E2 (CCNE2) and thymidylate synthetase (TYMS), two genes expressed in the G1/S transition of the cell cycle. CHD8 was also able to co-activate the CCNE2 promoter in transient transfection experiments. Chromatin immunoprecipitation experiments demonstrated that CHD8 binds directly to the 5' region of both CCNE2 and TYMS genes. Interestingly, both RNA polymerase II (RNAPII) and CHD8 bind constitutively to the 5' promoter-proximal region of CCNE2, regardless of the cell-cycle phase and, therefore, of the expression of CCNE2. The tandem chromodomains of CHD8 bind in vitro specifically to histone H3 di-methylated at lysine 4. However, CHD8 depletion does not affect the methylation levels of this residue. We also show that CHD8 associates with the elongating form of RNAPII, which is phosphorylated in its carboxy-terminal domain (CTD). Furthermore, CHD8-depleted cells are hypersensitive to drugs that inhibit RNAPII phosphorylation at serine 2, suggesting that CHD8 is required for an early step of the RNAPII transcription cycle.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1086 1087 1086 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
The packaging of eukaryotic DNA into nucleosomes and higher order structures represents an obstacle for transcription initiation and elongation (1,2). Different nuclear machineries are responsible for the reorganization of interactions within the chromatin which allows specific and general transcription factors to gain access to their targets in the DNA and to carry out gene transcription in a tightly regulated manner. A specific type of chromatin remodeling machine uses the energy of ATP hydrolysis to alter interactions between histones and DNA within the nucleosome (3). It is believed that ATP-dependent chromatin remodeling machines (CRMs) are able to move nucleosomes, reorganize their structure and composition or even remove them (4). All ATP-dependent CRMs contain a DNA-dependent ATPase of the SNF2 family, which is considered as the catalytic subunit responsible for the remodeling. According to the sequence homology of their conserved ATPase domains, SNF2 proteins have been classified into distinct subfamilies such as SWI2/SNF2, ISWI, CHD1, Mi-2, CHD7, INO80, etc. (5).
###end p 4
###begin p 5
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6 B7 B8 B9 B10 B11 B12">6&#8211;12</xref>
###xml 395 403 395 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1224 1232 1224 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1258 1263 1258 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1344 1352 1344 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1442 1444 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1502 1509 1502 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Many authors have shown how ATP-dependent CRMs positively or negatively affect the formation of the transcription pre-initiation complex (6-12) but, on the contrary, little is known about how these enzymes may affect subsequent steps of the transcription cycle such as elongation or termination. The RNA polymerase II (RNAPII) complex is very inefficient at transcribing chromatinized templates in vitro (1). In fact, biochemical studies have revealed that nucleosomes represent a strong barrier against elongation, so that RNAPII stops at certain arrest sites near them, becoming blocked in a catalytically inactive state (13,14). Two elongation complexes, FACT (facilitates chromatin transcription) (15) and CTEA (chromatin transcription enabling activity) (16), have been shown to stimulate RNAPII passage through a nucleosome. However, whether ATP-dependent chromatin remodeling enzymes are also required to remodel nucleosomes during RNAPII elongation is still unclear. In this respect, Kingston and colleagues reported that the SWI/SNF complex, one of the best characterized ATP-dependent CRMs, which contains an ATPase of the SWI2/SNF2 subfamily, enhances HSF1-mediated stimulation of promoter-proximal paused RNAPII in vitro (17). Furthermore, Carey et al. also demonstrated a role for SWI/SNF and the related RSC complex in elongation in vitro, as they are able to release RNAPII from the blockade caused by a positioned nucleosome (18). Despite these facts, so far there is no clear evidence in vivo for a role of SWI/SNF-type CRMs in elongation.
###end p 5
###begin p 6
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 702 709 702 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 818 828 818 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 937 962 937 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schizosaccharomyces pombe</italic>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 208 213 <span type="species:ncbi:4932">yeast</span>
###xml 324 329 <span type="species:ncbi:4932">yeast</span>
###xml 818 828 <span type="species:ncbi:7227">Drosophila</span>
###xml 937 962 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
On the other hand, CHD1 (chromodomain-ATPase/helicase-DNA-binding domain 1), another SNF2-like ATPase belonging to the so called CHD1 subfamily, does appear to function in both elongation and termination. In yeast and flies CHD1 associates with highly active transcription sites (19,20). Furthermore, CHD1 mutant alleles in yeast are sensitive to 6-azauracil (21) and genetically interact with Set2 and Spt5, both involved in elongation (20,22). Finally, CHD1 physically associates with factors involved in elongation such as the polymerase II-associated complex (PAF), DSIF (DRB-sensitivity-inducing factor) and FACT (20,23,24). These results strongly indicate that CHD1 works as an elongation factor in vivo, although very little mechanistic data had been provided until recently, when Konev et al. (25) showed that Drosophila CHD1 is involved in histone H3.3 replacement in the transcriptionally silent male pronucleus. Moreover, the Schizosaccharomyces pombe homolog of CHD1, Hrp1, has been shown to function in loading of the centromere-specific H3 variant CENP-A (26). Therefore, CHD1 also may have a general role in replication-independent nucleosome assembly. The connection between this CHD1 function and its role in elongation remains unknown.
###end p 6
###begin p 7
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 875 877 872 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U6</italic>
###xml 925 927 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 928 930 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1042 1048 1036 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2)</italic>
###xml 1077 1082 1071 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS)</italic>
###xml 810 815 <span type="species:ncbi:9606">human</span>
In addition to CHD1, there are other eight CHD proteins in mammalian cells, which are classified into three subfamilies called CHD1 (CHD1 and CHD2), Mi-2 (CHD3 to CHD5) and CHD7 (CHD6 to CHD9) subfamilies (5,27). Here we have investigated the role of CHD8 in transcription. In addition to the typical helicase-like domain that characterizes the SNF2 family, CHD8 contains two tandem chromodomains within the amino-terminal half of the protein. Chromodomains are evolutionary conserved motifs involved in interactions with DNA, RNA or methylated lysines (28). Moreover, CHD8 also contains a SANT domain and two BRK domains with unclear functions. CHD8 has been shown to interact with CTCF and is required for CTCF-dependent insulator activity (29). Recently, it has also been shown that CHD8 interacts with the human proteins Staf and beta-catenin and contributes to regulate U6 and beta-catenin-dependent gene transcription (30,31). We found that CHD8 is required for cell proliferation. CHD8 positively controls the expression of cyclin E2 (CCNE2) and thymidylate synthetase (TYMS), two genes specifically expressed in the G1/S transition. Furthermore, CHD8 associates constitutively with the promoter and the transcribed 5' region of its target genes and interacts with elongating RNAPII, suggesting a role for this protein in transcription elongation.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Cell culture, growth curves and cell-cycle analyses
###end title 9
###begin p 10
###xml 224 225 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 259 260 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 576 578 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 98 104 <span type="species:ncbi:9913">bovine</span>
All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 7% fetal bovine serum, 100 units/ml penicillin and 100 microg/ml streptomycin, and were cultivated in a 37degreesC incubator with 5% CO2. For cell growth analysis, 2 x 105 C33KD1, C33KD2 and HeLaKD1 cells were seeded in 10 cm plates, with or without 2 microg/ml doxycycline (Sigma). At the indicated times cells were collected and counted using a Neubauer haemocytometer. Cell-cycle analysis was carried out using BD FACSCalibur flow cytometer (BD Biosciences), as previously described (32). When required cultures were treated with Flavopiridol (Sanofi-Aventis) or DRB (Sigma) at the indicated final concentration. Stock solution of Flavopiridol 10 mM was prepared in DMSO. For BrdU cell proliferation assays, cells were labeled with 10 mM BrdU during 15 min. BrdU incorporation was detected using the 5-bromo-2'-deoxy-uridine Labeling and Detection Kit I (Roche).
###end p 10
###begin p 11
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Cells were synchronized by double thymidine blocking as previously described (33), except that samples were taken at the following times after blocking release: t = 0 h (G1/S phase), t = 4 h (S phase), t = 14 h (early G1 phase) and t = 18 h (late G1 phase). The cell-cycle stage of each population was determined by flow cytometry analysis.
###end p 11
###begin title 12
Plasmid constructs
###end title 12
###begin p 13
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bgl</italic>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hind</italic>
To make pTER-CHD8-1 and pTER-CHD8-2, annealed gene-specific oligonucleotides encoding shRNA1 or shRNA2 () were ligated into pTER (34) and pSUPER vectors (35) previously digested with BglII and HindIII.
###end p 13
###begin p 14
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blp</italic>
###xml 121 124 121 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 394 397 394 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 440 444 440 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 500 503 500 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 505 508 505 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 657 660 657 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 666 669 666 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 322 327 <span type="species:ncbi:9606">Human</span>
The pRSV-CHD8 expression vector containing the CHD8 protein (2581 amino acids) was constructed as follows: first, a BlpI-NotI fragment from pBC SK (+)-KIAA1564 (provided by the Kazusa DNA Research Institute, Japan) was cloned into a pTriplEx2 (BD Biosciences) containing the EST AV762074 (provided by the Chinese National Human Genome Center, China) to constitute pTriplEx2-CHD8. After that, a PmlI restriction site was inserted before the CHD8 sequence using standard PCR techniques and, finally, a PmlI-NotI fragment from the former construct was cloned into a pAdRSV-Sp (36) derivative containing an in-frame FLAG epitope, and previously linearized with PmlI and NotI.
###end p 14
###begin p 15
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hind</italic>
###xml 197 200 197 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
For Luciferase reporter assays, pCycE2 was constructed by inserting a PCR fragment ranging from nucleotide -960 to nucleotide +60 of CCNE2 gene into pCycE (37) previously digested with HindIII and NotI.
###end p 15
###begin p 16
To make pGEX-CD1, pGEX-CD2, pGEX-CD1+CD2, and pGEX-CD1+mutCD2, pGEX-mutCD1+CD2 fragments encoding CHD8 CD1 (residues 629-715), CD2 (residues 710-785), CD1+CD2 (residues 629-785), CD1+mutCD2 (residues 629-785, W751L, Y756L), and mutCD1+CD2 (residues 629-785, Y672L, Y675L, Y677L), were cloned into a pGEX-4T-2 vector (GE Healthcare) using standard PCR techniques. All constructs were verified by DNA sequencing.
###end p 16
###begin title 17
Generation of inducible knockdown cell lines
###end title 17
###begin p 18
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
To generate inducible shRNA CHD8 knockdown cell lines, C33A and HeLa cells were co-transfected with pCDNA6TR (Invitrogen) and pTER-CHD8-1. Resistant clones were selected in the presence of 100 microg/ml Zeocin and 5 microg/ml Blasticidin, and tested for their ability to down-regulate CHD8 by immunoblotting, at different times after the addition of 2 microg/ml Dox.
###end p 18
###begin title 19
ChIP assays
###end title 19
###begin p 20
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 459 471 456 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actin (ACTB)</italic>
ChIP assays were basically performed as described by Upstate/Millipore (). ChIP data are the average of 12-18 real-time PCR quantifications from two to three independent experiments. Real-time PCRs were performed in an Applied Biosystems 7500 FAST Real-Time PCR System, using the Applied Biosystems Power SYBR Green Master Mix and protocols. ChIP was quantified relative to inputs using the method described in (38). Specific primers for CCNE2, TYMS and beta-Actin (ACTB) were designed using the Primer Express 3.0 software (Applied Biosystems) and are described in the .
###end p 20
###begin p 21
Antibodies used in ChIP assays include polyclonal alpha-CHD8 (30 microl per sample), alpha-H3K4me3, alpha-H3K4me2 (Upstate/Millipore) (5 microl per sample) and alpha-RNAPII N-20 (Santa Cruz Biotechnologies) (5 microl per sample).
###end p 21
###begin title 22
Antibodies, immunoblotting and immunoprecipitations
###end title 22
###begin p 23
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 151 157 <span type="species:ncbi:9986">rabbit</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
Immunobloting experiments were carried out as previously described (39). Co-immunoprecipitations were carried out as described (40). To detect CHD8, a rabbit polyclonal serum raised against a GST fusion protein containing human CHD8 residues 16-227 was used. Commercial antibodies used for immunoblotting include alpha-CCNE2 (Cell Signalling Technology), alpha-E2F1 (KH95), alpha-SPT5 (H-300), alpha-BRAF35 (4.21), alpha-RNAPII (N-20) (Santa Cruz Biotechnology), alpha-Ser5-P-RNAPII (CTD4H8, Upstate-Millipore), alpha-RNAPIIa (8WG16), alpha-Ser2-P-RNAPII (H5) and alpha-Ser5-P-RNAPII (H14) (Covance).
###end p 23
###begin title 24
Gene-expression analysis
###end title 24
###begin p 25
RNA was isolated using the RNeasy Mini kit (Qiagen). cDNA was synthesized from 3 microg of total RNA with the SuperScript First-Strand Synthesis system for RT-PCR (Invitrogen). One-twentieth of the reaction was used for PCR amplification with specific primers spanning an intron as a control for DNA contamination. To keep the amplification within the quantitative range, the number of cycles, usually 12-25, was set up for each experiment. Products were detected by Southern blot, using an InstantImager Electronic Autoradiography device (Packard Instrument) for quantification of radioactive areas. Gene-specific primers used in RT-PCR experiments are described in the .
###end p 25
###begin title 26
Microarray gene-expression analysis
###end title 26
###begin p 27
###xml 433 438 <span type="species:ncbi:9606">human</span>
Total RNA samples coming from C33KD2 cells cultured for 48 h either with or without 2 microg/ml doxycycline were used to generate complementary RNA labeled either with Cyanine 3 or Cyanine 5 with the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). Dye incorporation was determined with a NanoDrop spectrophotometer. Once labeling was completed, both samples were combined and hybridized to a whole human genome Agilent 44K 60-mer Oligo Microarray (Agilent Technologies) according to manufacturer's instructions. The experiment was performed in triplicate in order to achieve statistical significance. The microarrays were scanned on an Agilent G2565 scanner (Agilent Technologies) and images were extracted and quality assessed with the Agilent Feature Extraction software (Agilent Technologies). Data from the three individual hybridizations were normalized using the RMA algorithm, and the data were then further analyzed using the microarray software package Genespring GX 7.3 software (Agilent Technologies). Microarray data have been deposited in the GEO (Gene Expression Omnibus) database with the accession number GSE11422.
###end p 27
###begin title 28
Luciferase reporter assays
###end title 28
###begin p 29
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
For luciferase reporter assays, 2 x 105 COS-7 cells per well were seeded in six-well plates and co-transfected with 200 ng of the luciferase reporter vectors, pCycE2, or pMMTV-Luc, and increasing quantities of pRSV-CHD8, by using Fugene-6 (Roche). Luciferase activity was determined 36 h after transfection with Lysis Solution 1x (Promega), Luciferase Substrate (Promega) and a GloMax 20/20 luminometer (Promega), following the manufacturer's instructions. All transfections were normalized by measuring beta-galactosidase activity of the samples. Data are the average of at least three independent experiments and error bars indicate standard deviation.
###end p 29
###begin title 30
Peptide binding assays
###end title 30
###begin p 31
Sequences encoding CHD8 CD1 (residues 629-715), CD2 (residues 710-785) CD1+CD2 (residues 629-785), CD1+mutCD2 (residues 629-785, W751L, Y756L) and mutCD1+CD2 (residues 629-785, Y672L, Y675L, Y677L) were expressed as GST fusion proteins in BL21 (DE3) bacterial cells and purified using standard procedures. For binding assays, 0.5 microg of each GST fusion protein were incubated with 2 microg biotinylated di-methylated Lys 4, tri-methylated Lys 4, di-methylated Lys 9 or unmodified histone H3 peptides (Upstate), in a 200 microl reaction using 156 microl of interaction buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 1 mM EDTA, 0.2% (v/v) NP-40, 0.25% BSA and protease inhibitors), for 2 h at 4degreesC with rotation. Then, 15 microl Dynabeads M-280 Streptavidin (Dynal Biotech) were added to the samples for an additional hour and, after three washes in interaction buffer, each one was eluted with 20 microl Laemmli buffer 2x and subjected to western blot analysis using an alpha-GST antibody.
###end p 31
###begin title 32
RESULTS
###end title 32
###begin title 33
Depletion of CHD8 impairs cell proliferation
###end title 33
###begin p 34
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 433 441 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD6</italic>
###xml 539 543 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD7</italic>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD9</italic>
###xml 928 936 928 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1502 1510 1490 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1743 1751 1731 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1857 1866 1845 1854 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 2018 2019 2006 2007 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2191 2192 2171 2172 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2368 2369 2348 2349 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2570 2571 2550 2551 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1866 2907 1854 2883 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="35">Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable transfection of C33A cells. (<bold>A</bold>) Immunoblot analysis of Dox-treated (+) and non-treated (&#8722;) cells after 72 h, using &#945;-CHD8 antibody. &#945;-Ser2-P RNAPII antibody (H5) was used as a loading control. (<bold>B</bold>) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are the average of three independent experiments. Error bars represent standard deviation. (<bold>C</bold>) Flow cytometry analysis of asynchronous C33KD1 and C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experiments. (<bold>D</bold>) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunofluorescence using &#945;-BrdU antibodies. Numbers are the average of two independent experiments.</p>
###xml 1866 2907 1854 2883 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="35">Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable transfection of C33A cells. (<bold>A</bold>) Immunoblot analysis of Dox-treated (+) and non-treated (&#8722;) cells after 72 h, using &#945;-CHD8 antibody. &#945;-Ser2-P RNAPII antibody (H5) was used as a loading control. (<bold>B</bold>) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are the average of three independent experiments. Error bars represent standard deviation. (<bold>C</bold>) Flow cytometry analysis of asynchronous C33KD1 and C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experiments. (<bold>D</bold>) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunofluorescence using &#945;-BrdU antibodies. Numbers are the average of two independent experiments.</p></caption>
###xml 2907 2907 2883 2883 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp101f1"/>
###xml 1857 2907 1845 2883 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="35">Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable transfection of C33A cells. (<bold>A</bold>) Immunoblot analysis of Dox-treated (+) and non-treated (&#8722;) cells after 72 h, using &#945;-CHD8 antibody. &#945;-Ser2-P RNAPII antibody (H5) was used as a loading control. (<bold>B</bold>) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are the average of three independent experiments. Error bars represent standard deviation. (<bold>C</bold>) Flow cytometry analysis of asynchronous C33KD1 and C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experiments. (<bold>D</bold>) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunofluorescence using &#945;-BrdU antibodies. Numbers are the average of two independent experiments.</p></caption><graphic xlink:href="gkp101f1"/></fig>
###xml 229 234 <span type="species:ncbi:9606">human</span>
In order to identify CHD8 functions we decided to decrease the expression of CHD8 by a doxycycline-regulated inducible shRNA expression vector (34). For that, two knockdown stable cell lines (C33KD1 and C33KD2) were derived from human C33A cervical carcinoma cells. Both lines showed a significant reduction in the level of CHD8 expression upon doxycycline (Dox) addition (85% reduction after 72 h), as determined by immunoblotting (Figure 1A). RT-PCR experiments demonstrated that expression of the closely related paralogous genes CHD6, CHD7 and CHD9 was unaffected, indicating that the knockdown was specific (). To determine whether reduced CHD8 levels affect cell proliferation, the growth rate of C33KD1 and C33KD2 cell lines was studied in the presence or the absence of Dox. Both cell lines exhibited a slower growth rate under conditions of CHD8 depletion, indicating that CHD8 is required for C33A cell proliferation (Figure 1B). As a control, we verified that Dox had no effect on the growth rate of C33A cells (data not shown). To extend our results to another cell line we generated knockdown HeLa clones that showed identical defects in proliferation under conditions of CHD8 depletion (). FACS analysis of proliferating C33KD1 and C33KD2 cells demonstrated that knockdown of CHD8 reduced the S-phase cell population from approximately40% to 32%, with a concomitant increase in the G1 cell population from about 40-50%. Meanwhile, the G2/M cell population remained essentially unchanged (Figure 1C). Consistently, BrdU incorporation experiments revealed that upon a 15-min pulse of BrdU around 50% of the cells were able to incorporate BrdU in the absence of Dox but only about 35% of the CHD8-depleted cells were BrdU-positive (Figure 1D). These data suggest that CHD8 positively regulates the cell cycle by facilitating the G1/S transition. Figure 1.Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable transfection of C33A cells. (A) Immunoblot analysis of Dox-treated (+) and non-treated (-) cells after 72 h, using alpha-CHD8 antibody. alpha-Ser2-P RNAPII antibody (H5) was used as a loading control. (B) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are the average of three independent experiments. Error bars represent standard deviation. (C) Flow cytometry analysis of asynchronous C33KD1 and C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experiments. (D) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunofluorescence using alpha-BrdU antibodies. Numbers are the average of two independent experiments.
###end p 34
###begin p 35
###xml 152 153 152 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 325 326 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 502 503 494 495 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 704 705 696 697 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable transfection of C33A cells. (A) Immunoblot analysis of Dox-treated (+) and non-treated (-) cells after 72 h, using alpha-CHD8 antibody. alpha-Ser2-P RNAPII antibody (H5) was used as a loading control. (B) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are the average of three independent experiments. Error bars represent standard deviation. (C) Flow cytometry analysis of asynchronous C33KD1 and C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experiments. (D) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunofluorescence using alpha-BrdU antibodies. Numbers are the average of two independent experiments.
###end p 35
###begin title 36
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
CHD8 contributes to the expression of CCNE2 and TYMS genes
###end title 36
###begin p 37
###xml 554 555 554 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 630 631 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 813 817 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 1213 1218 1211 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1248 1252 1246 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 1318 1320 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 1379 1387 1377 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1402 1409 1400 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1742 1747 1740 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE1</italic>
###xml 1760 1765 1758 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNA2</italic>
###xml 1777 1780 1775 1778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK1</italic>
###xml 1800 1804 1798 1802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 1808 1812 1806 1810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCNA</italic>
###xml 1871 1879 1869 1877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1938 1943 1936 1941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1948 1952 1946 1950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 2153 2157 2151 2155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 2210 2219 2208 2217 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 2265 2269 2263 2267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 2274 2279 2272 2277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 2288 2289 2286 2287 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2350 2380 2348 2378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS, CCNE2, CCNE1, CCNA2, TK1</italic>
###xml 2494 2499 2489 2494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB)</italic>
###xml 2583 2584 2578 2579 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2656 2660 2651 2655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 2862 2863 2857 2858 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 3088 3089 3079 3080 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 3095 3100 3086 3091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 2219 3582 2217 3547 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="38">Depletion of CHD8 leads to down-regulation of <italic>TYMS</italic> and <italic>CCNE2</italic> genes. (<bold>A</bold>) Transcript levels of genes induced at the G1/S transition (<italic>TYMS, CCNE2, CCNE1, CCNA2, TK1</italic>) were analyzed by RT&#8211;PCR in Dox-treated (+) or non-treated (&#8722;) C33KD2 cells, at the indicated times. &#946;-Actin (<italic>ACTB)</italic> transcript levels were also determined as a control for the amount of input cDNA. (<bold>B</bold>) Quantification of signals shown in (A). Values were normalized to the <italic>ACTB</italic> gene transcript level. The level of cDNA amplified in Dox non-treated cells (&#8722;) was considered 100%. Values are the average of three independent experiments. Bars indicate standard error of the mean. (<bold>C</bold>) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were analyzed by immunoblot in C33KD2 cells treated (+) or non-treated (&#8722;) with Dox during the indicated time. &#945;-Ser2-P-RNAPII antibody (H5) was used as a loading control. (<bold>D</bold>) The <italic>CCNE2</italic> promoter is activated by CHD8. COS-7 cells were transfected with 0.2 &#181;g of pCycE2-LUC plasmid along with 0.3 or 0.7 &#181;g of pRSV-CHD8 plasmid. 0.2 &#181;g of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector (0.2 &#181;g) and with or without 0.7 &#181;g of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1 &#181;g/ml for 12 h. Values are the average of three independent experiments &#177; SD.</p>
###xml 2219 3582 2217 3547 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="38">Depletion of CHD8 leads to down-regulation of <italic>TYMS</italic> and <italic>CCNE2</italic> genes. (<bold>A</bold>) Transcript levels of genes induced at the G1/S transition (<italic>TYMS, CCNE2, CCNE1, CCNA2, TK1</italic>) were analyzed by RT&#8211;PCR in Dox-treated (+) or non-treated (&#8722;) C33KD2 cells, at the indicated times. &#946;-Actin (<italic>ACTB)</italic> transcript levels were also determined as a control for the amount of input cDNA. (<bold>B</bold>) Quantification of signals shown in (A). Values were normalized to the <italic>ACTB</italic> gene transcript level. The level of cDNA amplified in Dox non-treated cells (&#8722;) was considered 100%. Values are the average of three independent experiments. Bars indicate standard error of the mean. (<bold>C</bold>) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were analyzed by immunoblot in C33KD2 cells treated (+) or non-treated (&#8722;) with Dox during the indicated time. &#945;-Ser2-P-RNAPII antibody (H5) was used as a loading control. (<bold>D</bold>) The <italic>CCNE2</italic> promoter is activated by CHD8. COS-7 cells were transfected with 0.2 &#181;g of pCycE2-LUC plasmid along with 0.3 or 0.7 &#181;g of pRSV-CHD8 plasmid. 0.2 &#181;g of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector (0.2 &#181;g) and with or without 0.7 &#181;g of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1 &#181;g/ml for 12 h. Values are the average of three independent experiments &#177; SD.</p></caption>
###xml 3582 3582 3547 3547 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp101f2"/>
###xml 2210 3582 2208 3547 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="38">Depletion of CHD8 leads to down-regulation of <italic>TYMS</italic> and <italic>CCNE2</italic> genes. (<bold>A</bold>) Transcript levels of genes induced at the G1/S transition (<italic>TYMS, CCNE2, CCNE1, CCNA2, TK1</italic>) were analyzed by RT&#8211;PCR in Dox-treated (+) or non-treated (&#8722;) C33KD2 cells, at the indicated times. &#946;-Actin (<italic>ACTB)</italic> transcript levels were also determined as a control for the amount of input cDNA. (<bold>B</bold>) Quantification of signals shown in (A). Values were normalized to the <italic>ACTB</italic> gene transcript level. The level of cDNA amplified in Dox non-treated cells (&#8722;) was considered 100%. Values are the average of three independent experiments. Bars indicate standard error of the mean. (<bold>C</bold>) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were analyzed by immunoblot in C33KD2 cells treated (+) or non-treated (&#8722;) with Dox during the indicated time. &#945;-Ser2-P-RNAPII antibody (H5) was used as a loading control. (<bold>D</bold>) The <italic>CCNE2</italic> promoter is activated by CHD8. COS-7 cells were transfected with 0.2 &#181;g of pCycE2-LUC plasmid along with 0.3 or 0.7 &#181;g of pRSV-CHD8 plasmid. 0.2 &#181;g of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector (0.2 &#181;g) and with or without 0.7 &#181;g of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1 &#181;g/ml for 12 h. Values are the average of three independent experiments &#177; SD.</p></caption><graphic xlink:href="gkp101f2"/></fig>
###xml 3582 3590 3547 3555 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 3641 3645 3606 3610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 3590 3660 3555 3625 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="39">Selection of up- and down-regulated transcripts in <italic>CHD8</italic>-depleted cells</p>
###xml 3590 3660 3555 3625 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="39">Selection of up- and down-regulated transcripts in <italic>CHD8</italic>-depleted cells</p></caption>
###xml 3660 3671 3625 3636 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Gene symbol</th>
###xml 3671 3695 3636 3660 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Gene product description</th>
###xml 3695 3706 3660 3671 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Fold change</th>
###xml 3660 3706 3625 3671 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><th rowspan="1" colspan="1">Gene symbol</th><th rowspan="1" colspan="1">Gene product description</th><th rowspan="1" colspan="1">Fold change</th></tr>
###xml 3660 3706 3625 3671 <thead xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><th rowspan="1" colspan="1">Gene symbol</th><th rowspan="1" colspan="1">Gene product description</th><th rowspan="1" colspan="1">Fold change</th></tr></thead>
###xml 3706 3724 3671 3689 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Up-regulated genes</td>
###xml 3724 3724 3689 3689 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3724 3724 3689 3689 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3706 3724 3671 3689 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Up-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr>
###xml 3724 3728 3689 3693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CSH1</italic>
###xml 3724 3728 3689 3693 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>CSH1</italic></td>
###xml 3728 3765 3693 3730 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Chorionic somatomammotropin hormone 1</td>
###xml 3765 3771 3730 3736 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2.7321</td>
###xml 3724 3771 3689 3736 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>CSH1</italic></td><td rowspan="1" colspan="1">Chorionic somatomammotropin hormone 1</td><td rowspan="1" colspan="1">2.7321</td></tr>
###xml 3771 3776 3736 3741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NUPL1</italic>
###xml 3771 3776 3736 3741 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>NUPL1</italic></td>
###xml 3776 3794 3741 3759 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Nucleoporin like 1</td>
###xml 3794 3800 3759 3765 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.8661</td>
###xml 3771 3800 3736 3765 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>NUPL1</italic></td><td rowspan="1" colspan="1">Nucleoporin like 1</td><td rowspan="1" colspan="1">1.8661</td></tr>
###xml 3800 3813 3765 3778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DKFZp451J1719</italic>
###xml 3800 3813 3765 3778 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>DKFZp451J1719</italic></td>
###xml 3813 3849 3778 3814 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">YOD1 deubiquinating enzyme 1 homolog</td>
###xml 3849 3855 3814 3820 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.8150</td>
###xml 3800 3855 3765 3820 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>DKFZp451J1719</italic></td><td rowspan="1" colspan="1">YOD1 deubiquinating enzyme 1 homolog</td><td rowspan="1" colspan="1">1.8150</td></tr>
###xml 3855 3863 3820 3828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARHGEF12</italic>
###xml 3855 3863 3820 3828 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>ARHGEF12</italic></td>
###xml 3863 3910 3828 3875 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Rho guanine nucleotide exchange factor (GEF) 12</td>
###xml 3910 3916 3875 3881 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.6586</td>
###xml 3855 3916 3820 3881 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>ARHGEF12</italic></td><td rowspan="1" colspan="1">Rho guanine nucleotide exchange factor (GEF) 12</td><td rowspan="1" colspan="1">1.6586</td></tr>
###xml 3916 3921 3881 3886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRADD</italic>
###xml 3916 3921 3881 3886 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>CRADD</italic></td>
###xml 3921 3980 3886 3945 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">CASP2 and RIPK1 domain containing adaptor with death domain</td>
###xml 3980 3986 3945 3951 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.5052</td>
###xml 3916 3986 3881 3951 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>CRADD</italic></td><td rowspan="1" colspan="1">CASP2 and RIPK1 domain containing adaptor with death domain</td><td rowspan="1" colspan="1">1.5052</td></tr>
###xml 3986 3991 3951 3956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASA2</italic>
###xml 3986 3991 3951 3956 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>RASA2</italic></td>
###xml 3991 4018 3956 3983 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">RAS p21 protein activator 2</td>
###xml 4018 4024 3983 3989 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.4044</td>
###xml 3986 4024 3951 3989 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>RASA2</italic></td><td rowspan="1" colspan="1">RAS p21 protein activator 2</td><td rowspan="1" colspan="1">1.4044</td></tr>
###xml 4024 4044 3989 4009 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Down-regulated genes</td>
###xml 4044 4044 4009 4009 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 4044 4044 4009 4009 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 4024 4044 3989 4009 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Down-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr>
###xml 4044 4051 4009 4016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK2AP1</italic>
###xml 4044 4051 4009 4016 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>CDK2AP1</italic></td>
###xml 4051 4076 4016 4041 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">CDK2-associated protein 1</td>
###xml 4076 4083 4041 4048 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.71203</td>
###xml 4044 4083 4009 4048 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>CDK2AP1</italic></td><td rowspan="1" colspan="1">CDK2-associated protein 1</td><td rowspan="1" colspan="1">0.71203</td></tr>
###xml 4083 4088 4048 4053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DHX29</italic>
###xml 4083 4088 4048 4053 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>DHX29</italic></td>
###xml 4088 4129 4053 4094 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">DEAH (Asp-Glu-Ala-His) box polypeptide 29</td>
###xml 4129 4136 4094 4101 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.70222</td>
###xml 4083 4136 4048 4101 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>DHX29</italic></td><td rowspan="1" colspan="1">DEAH (Asp-Glu-Ala-His) box polypeptide 29</td><td rowspan="1" colspan="1">0.70222</td></tr>
###xml 4136 4141 4101 4106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP11</italic>
###xml 4136 4141 4101 4106 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>USP11</italic></td>
###xml 4141 4171 4106 4136 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Ubiquitin specific protease 11</td>
###xml 4171 4178 4136 4143 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.69737</td>
###xml 4136 4178 4101 4143 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>USP11</italic></td><td rowspan="1" colspan="1">Ubiquitin specific protease 11</td><td rowspan="1" colspan="1">0.69737</td></tr>
###xml 4178 4183 4143 4148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF13</italic>
###xml 4178 4183 4143 4148 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>KLF13</italic></td>
###xml 4183 4205 4148 4170 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Kruppel-like factor 13</td>
###xml 4205 4212 4170 4177 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.69737</td>
###xml 4178 4212 4143 4177 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>KLF13</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 13</td><td rowspan="1" colspan="1">0.69737</td></tr>
###xml 4212 4217 4177 4182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NUCKS</italic>
###xml 4212 4217 4177 4182 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>NUCKS</italic></td>
###xml 4217 4287 4182 4252 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate</td>
###xml 4287 4294 4252 4259 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.69255</td>
###xml 4212 4294 4177 4259 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>NUCKS</italic></td><td rowspan="1" colspan="1">Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate</td><td rowspan="1" colspan="1">0.69255</td></tr>
###xml 4294 4298 4259 4263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR1</italic>
###xml 4294 4298 4259 4263 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>ROR1</italic></td>
###xml 4298 4345 4263 4310 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Receptor tyrosine kinase-like orphan receptor 1</td>
###xml 4345 4352 4310 4317 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.67830</td>
###xml 4294 4352 4259 4317 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>ROR1</italic></td><td rowspan="1" colspan="1">Receptor tyrosine kinase-like orphan receptor 1</td><td rowspan="1" colspan="1">0.67830</td></tr>
###xml 4352 4357 4317 4322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 4352 4357 4317 4322 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>CCNE2</italic></td>
###xml 4357 4366 4322 4331 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Cyclin E2</td>
###xml 4366 4373 4331 4338 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.67362</td>
###xml 4352 4373 4317 4338 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>CCNE2</italic></td><td rowspan="1" colspan="1">Cyclin E2</td><td rowspan="1" colspan="1">0.67362</td></tr>
###xml 4373 4378 4338 4343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF15</italic>
###xml 4373 4378 4338 4343 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>KLF15</italic></td>
###xml 4378 4400 4343 4365 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Kruppel-like factor 15</td>
###xml 4400 4407 4365 4372 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.66896</td>
###xml 4373 4407 4338 4372 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>KLF15</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 15</td><td rowspan="1" colspan="1">0.66896</td></tr>
###xml 4407 4414 4372 4379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PORIMIN</italic>
###xml 4407 4414 4372 4379 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>PORIMIN</italic></td>
###xml 4414 4464 4379 4429 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Pro-oncosis receptor inducing membrane injury gene</td>
###xml 4464 4471 4429 4436 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.66896</td>
###xml 4407 4471 4372 4436 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>PORIMIN</italic></td><td rowspan="1" colspan="1">Pro-oncosis receptor inducing membrane injury gene</td><td rowspan="1" colspan="1">0.66896</td></tr>
###xml 4471 4477 4436 4442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ZNF655</italic>
###xml 4471 4477 4436 4442 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>ZNF655</italic></td>
###xml 4477 4500 4442 4465 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Zinc finger protein 655</td>
###xml 4500 4507 4465 4472 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.66896</td>
###xml 4471 4507 4436 4472 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>ZNF655</italic></td><td rowspan="1" colspan="1">Zinc finger protein 655</td><td rowspan="1" colspan="1">0.66896</td></tr>
###xml 4507 4513 4472 4478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGPAT3</italic>
###xml 4507 4513 4472 4478 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>AGPAT3</italic></td>
###xml 4513 4559 4478 4524 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1-Acylglycerol-3-phosphate O-acyltransferase 3</td>
###xml 4559 4566 4524 4531 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.64171</td>
###xml 4507 4566 4472 4531 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>AGPAT3</italic></td><td rowspan="1" colspan="1">1-Acylglycerol-3-phosphate O-acyltransferase 3</td><td rowspan="1" colspan="1">0.64171</td></tr>
###xml 4566 4570 4531 4535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 4566 4570 4531 4535 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>CHD8</italic></td>
###xml 4570 4613 4535 4578 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Chromodomain helicase DNA binding protein 8</td>
###xml 4613 4620 4578 4585 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.63728</td>
###xml 4566 4620 4531 4585 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>CHD8</italic></td><td rowspan="1" colspan="1">Chromodomain helicase DNA binding protein 8</td><td rowspan="1" colspan="1">0.63728</td></tr>
###xml 4620 4623 4585 4588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NIN</italic>
###xml 4620 4623 4585 4588 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>NIN</italic></td>
###xml 4623 4657 4588 4622 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Ninein (GSK3B interacting protein)</td>
###xml 4657 4664 4622 4629 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.62417</td>
###xml 4620 4664 4585 4629 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>NIN</italic></td><td rowspan="1" colspan="1">Ninein (GSK3B interacting protein)</td><td rowspan="1" colspan="1">0.62417</td></tr>
###xml 4664 4668 4629 4633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 4664 4668 4629 4633 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>TYMS</italic></td>
###xml 4668 4690 4633 4655 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Thymidylate synthetase</td>
###xml 4690 4697 4655 4662 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.61132</td>
###xml 4664 4697 4629 4662 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>TYMS</italic></td><td rowspan="1" colspan="1">Thymidylate synthetase</td><td rowspan="1" colspan="1">0.61132</td></tr>
###xml 4697 4703 4662 4668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRISP3</italic>
###xml 4697 4703 4662 4668 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>CRISP3</italic></td>
###xml 4703 4736 4668 4701 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Cysteine-rich secretory protein 3</td>
###xml 4736 4743 4701 4708 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.52851</td>
###xml 4697 4743 4662 4708 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>CRISP3</italic></td><td rowspan="1" colspan="1">Cysteine-rich secretory protein 3</td><td rowspan="1" colspan="1">0.52851</td></tr>
###xml 4743 4746 4708 4711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIN</italic>
###xml 4743 4746 4708 4711 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"><italic>KIN</italic></td>
###xml 4746 4795 4711 4760 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">KIN antigenic determinant of recA protein homolog</td>
###xml 4795 4802 4760 4767 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.35111</td>
###xml 4743 4802 4708 4767 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"><italic>KIN</italic></td><td rowspan="1" colspan="1">KIN antigenic determinant of recA protein homolog</td><td rowspan="1" colspan="1">0.35111</td></tr>
###xml 3706 4802 3671 4767 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1">Up-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>CSH1</italic></td><td rowspan="1" colspan="1">Chorionic somatomammotropin hormone 1</td><td rowspan="1" colspan="1">2.7321</td></tr><tr><td rowspan="1" colspan="1"><italic>NUPL1</italic></td><td rowspan="1" colspan="1">Nucleoporin like 1</td><td rowspan="1" colspan="1">1.8661</td></tr><tr><td rowspan="1" colspan="1"><italic>DKFZp451J1719</italic></td><td rowspan="1" colspan="1">YOD1 deubiquinating enzyme 1 homolog</td><td rowspan="1" colspan="1">1.8150</td></tr><tr><td rowspan="1" colspan="1"><italic>ARHGEF12</italic></td><td rowspan="1" colspan="1">Rho guanine nucleotide exchange factor (GEF) 12</td><td rowspan="1" colspan="1">1.6586</td></tr><tr><td rowspan="1" colspan="1"><italic>CRADD</italic></td><td rowspan="1" colspan="1">CASP2 and RIPK1 domain containing adaptor with death domain</td><td rowspan="1" colspan="1">1.5052</td></tr><tr><td rowspan="1" colspan="1"><italic>RASA2</italic></td><td rowspan="1" colspan="1">RAS p21 protein activator 2</td><td rowspan="1" colspan="1">1.4044</td></tr><tr><td rowspan="1" colspan="1">Down-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>CDK2AP1</italic></td><td rowspan="1" colspan="1">CDK2-associated protein 1</td><td rowspan="1" colspan="1">0.71203</td></tr><tr><td rowspan="1" colspan="1"><italic>DHX29</italic></td><td rowspan="1" colspan="1">DEAH (Asp-Glu-Ala-His) box polypeptide 29</td><td rowspan="1" colspan="1">0.70222</td></tr><tr><td rowspan="1" colspan="1"><italic>USP11</italic></td><td rowspan="1" colspan="1">Ubiquitin specific protease 11</td><td rowspan="1" colspan="1">0.69737</td></tr><tr><td rowspan="1" colspan="1"><italic>KLF13</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 13</td><td rowspan="1" colspan="1">0.69737</td></tr><tr><td rowspan="1" colspan="1"><italic>NUCKS</italic></td><td rowspan="1" colspan="1">Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate</td><td rowspan="1" colspan="1">0.69255</td></tr><tr><td rowspan="1" colspan="1"><italic>ROR1</italic></td><td rowspan="1" colspan="1">Receptor tyrosine kinase-like orphan receptor 1</td><td rowspan="1" colspan="1">0.67830</td></tr><tr><td rowspan="1" colspan="1"><italic>CCNE2</italic></td><td rowspan="1" colspan="1">Cyclin E2</td><td rowspan="1" colspan="1">0.67362</td></tr><tr><td rowspan="1" colspan="1"><italic>KLF15</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 15</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>PORIMIN</italic></td><td rowspan="1" colspan="1">Pro-oncosis receptor inducing membrane injury gene</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>ZNF655</italic></td><td rowspan="1" colspan="1">Zinc finger protein 655</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>AGPAT3</italic></td><td rowspan="1" colspan="1">1-Acylglycerol-3-phosphate O-acyltransferase 3</td><td rowspan="1" colspan="1">0.64171</td></tr><tr><td rowspan="1" colspan="1"><italic>CHD8</italic></td><td rowspan="1" colspan="1">Chromodomain helicase DNA binding protein 8</td><td rowspan="1" colspan="1">0.63728</td></tr><tr><td rowspan="1" colspan="1"><italic>NIN</italic></td><td rowspan="1" colspan="1">Ninein (GSK3B interacting protein)</td><td rowspan="1" colspan="1">0.62417</td></tr><tr><td rowspan="1" colspan="1"><italic>TYMS</italic></td><td rowspan="1" colspan="1">Thymidylate synthetase</td><td rowspan="1" colspan="1">0.61132</td></tr><tr><td rowspan="1" colspan="1"><italic>CRISP3</italic></td><td rowspan="1" colspan="1">Cysteine-rich secretory protein 3</td><td rowspan="1" colspan="1">0.52851</td></tr><tr><td rowspan="1" colspan="1"><italic>KIN</italic></td><td rowspan="1" colspan="1">KIN antigenic determinant of recA protein homolog</td><td rowspan="1" colspan="1">0.35111</td></tr></tbody>
###xml 3660 4802 3625 4767 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Gene symbol</th><th rowspan="1" colspan="1">Gene product description</th><th rowspan="1" colspan="1">Fold change</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Up-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>CSH1</italic></td><td rowspan="1" colspan="1">Chorionic somatomammotropin hormone 1</td><td rowspan="1" colspan="1">2.7321</td></tr><tr><td rowspan="1" colspan="1"><italic>NUPL1</italic></td><td rowspan="1" colspan="1">Nucleoporin like 1</td><td rowspan="1" colspan="1">1.8661</td></tr><tr><td rowspan="1" colspan="1"><italic>DKFZp451J1719</italic></td><td rowspan="1" colspan="1">YOD1 deubiquinating enzyme 1 homolog</td><td rowspan="1" colspan="1">1.8150</td></tr><tr><td rowspan="1" colspan="1"><italic>ARHGEF12</italic></td><td rowspan="1" colspan="1">Rho guanine nucleotide exchange factor (GEF) 12</td><td rowspan="1" colspan="1">1.6586</td></tr><tr><td rowspan="1" colspan="1"><italic>CRADD</italic></td><td rowspan="1" colspan="1">CASP2 and RIPK1 domain containing adaptor with death domain</td><td rowspan="1" colspan="1">1.5052</td></tr><tr><td rowspan="1" colspan="1"><italic>RASA2</italic></td><td rowspan="1" colspan="1">RAS p21 protein activator 2</td><td rowspan="1" colspan="1">1.4044</td></tr><tr><td rowspan="1" colspan="1">Down-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>CDK2AP1</italic></td><td rowspan="1" colspan="1">CDK2-associated protein 1</td><td rowspan="1" colspan="1">0.71203</td></tr><tr><td rowspan="1" colspan="1"><italic>DHX29</italic></td><td rowspan="1" colspan="1">DEAH (Asp-Glu-Ala-His) box polypeptide 29</td><td rowspan="1" colspan="1">0.70222</td></tr><tr><td rowspan="1" colspan="1"><italic>USP11</italic></td><td rowspan="1" colspan="1">Ubiquitin specific protease 11</td><td rowspan="1" colspan="1">0.69737</td></tr><tr><td rowspan="1" colspan="1"><italic>KLF13</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 13</td><td rowspan="1" colspan="1">0.69737</td></tr><tr><td rowspan="1" colspan="1"><italic>NUCKS</italic></td><td rowspan="1" colspan="1">Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate</td><td rowspan="1" colspan="1">0.69255</td></tr><tr><td rowspan="1" colspan="1"><italic>ROR1</italic></td><td rowspan="1" colspan="1">Receptor tyrosine kinase-like orphan receptor 1</td><td rowspan="1" colspan="1">0.67830</td></tr><tr><td rowspan="1" colspan="1"><italic>CCNE2</italic></td><td rowspan="1" colspan="1">Cyclin E2</td><td rowspan="1" colspan="1">0.67362</td></tr><tr><td rowspan="1" colspan="1"><italic>KLF15</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 15</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>PORIMIN</italic></td><td rowspan="1" colspan="1">Pro-oncosis receptor inducing membrane injury gene</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>ZNF655</italic></td><td rowspan="1" colspan="1">Zinc finger protein 655</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>AGPAT3</italic></td><td rowspan="1" colspan="1">1-Acylglycerol-3-phosphate O-acyltransferase 3</td><td rowspan="1" colspan="1">0.64171</td></tr><tr><td rowspan="1" colspan="1"><italic>CHD8</italic></td><td rowspan="1" colspan="1">Chromodomain helicase DNA binding protein 8</td><td rowspan="1" colspan="1">0.63728</td></tr><tr><td rowspan="1" colspan="1"><italic>NIN</italic></td><td rowspan="1" colspan="1">Ninein (GSK3B interacting protein)</td><td rowspan="1" colspan="1">0.62417</td></tr><tr><td rowspan="1" colspan="1"><italic>TYMS</italic></td><td rowspan="1" colspan="1">Thymidylate synthetase</td><td rowspan="1" colspan="1">0.61132</td></tr><tr><td rowspan="1" colspan="1"><italic>CRISP3</italic></td><td rowspan="1" colspan="1">Cysteine-rich secretory protein 3</td><td rowspan="1" colspan="1">0.52851</td></tr><tr><td rowspan="1" colspan="1"><italic>KIN</italic></td><td rowspan="1" colspan="1">KIN antigenic determinant of recA protein homolog</td><td rowspan="1" colspan="1">0.35111</td></tr></tbody></table>
###xml 3582 4802 3547 4767 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="39">Selection of up- and down-regulated transcripts in <italic>CHD8</italic>-depleted cells</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Gene symbol</th><th rowspan="1" colspan="1">Gene product description</th><th rowspan="1" colspan="1">Fold change</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Up-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>CSH1</italic></td><td rowspan="1" colspan="1">Chorionic somatomammotropin hormone 1</td><td rowspan="1" colspan="1">2.7321</td></tr><tr><td rowspan="1" colspan="1"><italic>NUPL1</italic></td><td rowspan="1" colspan="1">Nucleoporin like 1</td><td rowspan="1" colspan="1">1.8661</td></tr><tr><td rowspan="1" colspan="1"><italic>DKFZp451J1719</italic></td><td rowspan="1" colspan="1">YOD1 deubiquinating enzyme 1 homolog</td><td rowspan="1" colspan="1">1.8150</td></tr><tr><td rowspan="1" colspan="1"><italic>ARHGEF12</italic></td><td rowspan="1" colspan="1">Rho guanine nucleotide exchange factor (GEF) 12</td><td rowspan="1" colspan="1">1.6586</td></tr><tr><td rowspan="1" colspan="1"><italic>CRADD</italic></td><td rowspan="1" colspan="1">CASP2 and RIPK1 domain containing adaptor with death domain</td><td rowspan="1" colspan="1">1.5052</td></tr><tr><td rowspan="1" colspan="1"><italic>RASA2</italic></td><td rowspan="1" colspan="1">RAS p21 protein activator 2</td><td rowspan="1" colspan="1">1.4044</td></tr><tr><td rowspan="1" colspan="1">Down-regulated genes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>CDK2AP1</italic></td><td rowspan="1" colspan="1">CDK2-associated protein 1</td><td rowspan="1" colspan="1">0.71203</td></tr><tr><td rowspan="1" colspan="1"><italic>DHX29</italic></td><td rowspan="1" colspan="1">DEAH (Asp-Glu-Ala-His) box polypeptide 29</td><td rowspan="1" colspan="1">0.70222</td></tr><tr><td rowspan="1" colspan="1"><italic>USP11</italic></td><td rowspan="1" colspan="1">Ubiquitin specific protease 11</td><td rowspan="1" colspan="1">0.69737</td></tr><tr><td rowspan="1" colspan="1"><italic>KLF13</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 13</td><td rowspan="1" colspan="1">0.69737</td></tr><tr><td rowspan="1" colspan="1"><italic>NUCKS</italic></td><td rowspan="1" colspan="1">Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate</td><td rowspan="1" colspan="1">0.69255</td></tr><tr><td rowspan="1" colspan="1"><italic>ROR1</italic></td><td rowspan="1" colspan="1">Receptor tyrosine kinase-like orphan receptor 1</td><td rowspan="1" colspan="1">0.67830</td></tr><tr><td rowspan="1" colspan="1"><italic>CCNE2</italic></td><td rowspan="1" colspan="1">Cyclin E2</td><td rowspan="1" colspan="1">0.67362</td></tr><tr><td rowspan="1" colspan="1"><italic>KLF15</italic></td><td rowspan="1" colspan="1">Kruppel-like factor 15</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>PORIMIN</italic></td><td rowspan="1" colspan="1">Pro-oncosis receptor inducing membrane injury gene</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>ZNF655</italic></td><td rowspan="1" colspan="1">Zinc finger protein 655</td><td rowspan="1" colspan="1">0.66896</td></tr><tr><td rowspan="1" colspan="1"><italic>AGPAT3</italic></td><td rowspan="1" colspan="1">1-Acylglycerol-3-phosphate O-acyltransferase 3</td><td rowspan="1" colspan="1">0.64171</td></tr><tr><td rowspan="1" colspan="1"><italic>CHD8</italic></td><td rowspan="1" colspan="1">Chromodomain helicase DNA binding protein 8</td><td rowspan="1" colspan="1">0.63728</td></tr><tr><td rowspan="1" colspan="1"><italic>NIN</italic></td><td rowspan="1" colspan="1">Ninein (GSK3B interacting protein)</td><td rowspan="1" colspan="1">0.62417</td></tr><tr><td rowspan="1" colspan="1"><italic>TYMS</italic></td><td rowspan="1" colspan="1">Thymidylate synthetase</td><td rowspan="1" colspan="1">0.61132</td></tr><tr><td rowspan="1" colspan="1"><italic>CRISP3</italic></td><td rowspan="1" colspan="1">Cysteine-rich secretory protein 3</td><td rowspan="1" colspan="1">0.52851</td></tr><tr><td rowspan="1" colspan="1"><italic>KIN</italic></td><td rowspan="1" colspan="1">KIN antigenic determinant of recA protein homolog</td><td rowspan="1" colspan="1">0.35111</td></tr></tbody></table></table-wrap>
To identify CHD8 target genes we compared the genome-wide expression profiling of C33KD2 cells after Dox addition with that of non-treated cells. For this purpose, cells were collected after only 48 h of Dox treatment, when CHD8 levels were about 40% of its original quantity (data not shown). This was thought to avoid secondary effects produced by a pronounced growth arrest and to increase the probability of identifying direct target genes. Three independent biological replicates were performed. Taking into consideration only transcripts with a log2(+Dox/-Dox expression ratio) >0.5 or <-0.5, with statistically significant P values </=0.01, 10 and 31 genes were found to be up-regulated and down-regulated, respectively, in CHD8-depleted cells compared to non-depleted cells (). As expected, levels of the CHD8 transcript were down-regulated in the CHD8-depleted cells. Efficiency of the microarray-based identification of CHD8-dependent genes was confirmed by RT-PCR analyses of a subset of misregulated genes (). Given the cell-cycle progression defects observed in the CHD8-depleted cells, we specifically focused on the cell-cycle-related genes among the CHD8-dependent ones. Interestingly, cyclin E2 (CCNE2) and thymidylate synthetase (TYMS), two E2F1-dependent genes expressed during the G1/S transition (41), were found to be down-regulated in CHD8-depleted cells (Figure 2A, B and C and Table 1). As a control, we verified that the expression of these two genes was not affected by Dox in C33A cells (data not shown). These results led us to explore the possibility that other genes specifically expressed in the G1/S cell-cycle transition were also misregulated in CHD8-depleted cells. Expression of none of the tested genes (CCNE1, cyclin E1; CCNA2, cyclin A; TK1, thymidine kinase; E2F1 or PCNA) was found to be significantly altered upon Dox addition (Figure 2A, B and C) indicating that the reduction in the amount of CCNE2 and TYMS transcripts is not a consequence of the G1 arrest provoked by the depletion of CHD8. Down-regulation of cyclin E2 was also verified using two independent shRNAs targeting two different regions of the CHD8 mRNA (), as well as in CHD8-depleted HeLa cells (). Figure 2.Depletion of CHD8 leads to down-regulation of TYMS and CCNE2 genes. (A) Transcript levels of genes induced at the G1/S transition (TYMS, CCNE2, CCNE1, CCNA2, TK1) were analyzed by RT-PCR in Dox-treated (+) or non-treated (-) C33KD2 cells, at the indicated times. beta-Actin (ACTB) transcript levels were also determined as a control for the amount of input cDNA. (B) Quantification of signals shown in (A). Values were normalized to the ACTB gene transcript level. The level of cDNA amplified in Dox non-treated cells (-) was considered 100%. Values are the average of three independent experiments. Bars indicate standard error of the mean. (C) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were analyzed by immunoblot in C33KD2 cells treated (+) or non-treated (-) with Dox during the indicated time. alpha-Ser2-P-RNAPII antibody (H5) was used as a loading control. (D) The CCNE2 promoter is activated by CHD8. COS-7 cells were transfected with 0.2 microg of pCycE2-LUC plasmid along with 0.3 or 0.7 microg of pRSV-CHD8 plasmid. 0.2 microg of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector (0.2 microg) and with or without 0.7 microg of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1 microg/ml for 12 h. Values are the average of three independent experiments +/- SD.Table 1.Selection of up- and down-regulated transcripts in CHD8-depleted cellsGene symbolGene product descriptionFold changeUp-regulated genesCSH1Chorionic somatomammotropin hormone 12.7321NUPL1Nucleoporin like 11.8661DKFZp451J1719YOD1 deubiquinating enzyme 1 homolog1.8150ARHGEF12Rho guanine nucleotide exchange factor (GEF) 121.6586CRADDCASP2 and RIPK1 domain containing adaptor with death domain1.5052RASA2RAS p21 protein activator 21.4044Down-regulated genesCDK2AP1CDK2-associated protein 10.71203DHX29DEAH (Asp-Glu-Ala-His) box polypeptide 290.70222USP11Ubiquitin specific protease 110.69737KLF13Kruppel-like factor 130.69737NUCKSNuclear ubiquitous casein kinase and cyclin-dependent kinase substrate0.69255ROR1Receptor tyrosine kinase-like orphan receptor 10.67830CCNE2Cyclin E20.67362KLF15Kruppel-like factor 150.66896PORIMINPro-oncosis receptor inducing membrane injury gene0.66896ZNF655Zinc finger protein 6550.66896AGPAT31-Acylglycerol-3-phosphate O-acyltransferase 30.64171CHD8Chromodomain helicase DNA binding protein 80.63728NINNinein (GSK3B interacting protein)0.62417TYMSThymidylate synthetase0.61132CRISP3Cysteine-rich secretory protein 30.52851KINKIN antigenic determinant of recA protein homolog0.35111
###end p 37
###begin p 38
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 131 161 131 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS, CCNE2, CCNE1, CCNA2, TK1</italic>
###xml 275 280 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB)</italic>
###xml 364 365 361 362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 437 441 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 643 644 640 641 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 869 870 862 863 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 876 881 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
Depletion of CHD8 leads to down-regulation of TYMS and CCNE2 genes. (A) Transcript levels of genes induced at the G1/S transition (TYMS, CCNE2, CCNE1, CCNA2, TK1) were analyzed by RT-PCR in Dox-treated (+) or non-treated (-) C33KD2 cells, at the indicated times. beta-Actin (ACTB) transcript levels were also determined as a control for the amount of input cDNA. (B) Quantification of signals shown in (A). Values were normalized to the ACTB gene transcript level. The level of cDNA amplified in Dox non-treated cells (-) was considered 100%. Values are the average of three independent experiments. Bars indicate standard error of the mean. (C) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were analyzed by immunoblot in C33KD2 cells treated (+) or non-treated (-) with Dox during the indicated time. alpha-Ser2-P-RNAPII antibody (H5) was used as a loading control. (D) The CCNE2 promoter is activated by CHD8. COS-7 cells were transfected with 0.2 microg of pCycE2-LUC plasmid along with 0.3 or 0.7 microg of pRSV-CHD8 plasmid. 0.2 microg of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector (0.2 microg) and with or without 0.7 microg of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1 microg/ml for 12 h. Values are the average of three independent experiments +/- SD.
###end p 38
###begin p 39
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
Selection of up- and down-regulated transcripts in CHD8-depleted cells
###end p 39
###begin p 40
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">luc</italic>
###xml 228 236 228 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 515 522 515 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 596 604 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 780 785 780 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 790 794 790 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 886 894 882 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 976 981 972 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1000 1008 996 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1088 1097 1084 1093 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 1154 1159 1150 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1164 1168 1160 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 1185 1186 1181 1182 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1382 1387 1370 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1389 1393 1377 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 1398 1402 1386 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 1507 1512 1495 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1526 1530 1514 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 1549 1553 1537 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 1562 1563 1550 1551 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1568 1569 1556 1557 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1594 1599 1582 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1608 1612 1596 1600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 1674 1675 1662 1663 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1707 1712 1695 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1865 1870 1853 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1097 2277 1093 2265 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="41">Analysis of the presence of CHD8 in the 5&#8242; region of the <italic>CCNE2</italic> and <italic>TYMS</italic> genes by ChIP. (<bold>A</bold>) Crosslinked DNA&#8211;protein complexes from C33A cells were immunoprecipitated with &#945;-CHD8 and &#945;-H3K4me3 (as a positive control). PCR amplification was performed with specific primers of the <italic>CCNE2</italic>, <italic>TYMS</italic> and <italic>ACTB</italic> genes. The center of PCR products relative to the transcription start sites is as follows: +836 for the <italic>CCNE2</italic>, +91 for the <italic>TYMS</italic> and +1294 for the <italic>ACTB</italic> genes. (<bold>B</bold> and <bold>C</bold>) Binding of CHD8 to the <italic>CCNE2</italic> (B) and <italic>TYMS</italic> (C) genes in C33KD2 cells treated or not with Dox for 72 h. (<bold>D</bold>) Distribution of CHD8 over the <italic>CCNE2</italic> gene in C33A cells. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. A diagram of the <italic>CCNE2</italic> gene is also shown. Black boxes correspond to coding exons while grey boxes correspond to the 5&#8242;UTR and 3&#8242;UTR. Transcription start point (+1) and ATG are also indicated. In (B), (C) and (D), immunoprecipitated DNA from three independent experiments was quantified using qPCR and expressed as percentage of the input (B and C) or as fold enrichment respect to the &#8722;11 058 amplicon (D). PI, pre-immune serum.</p>
###xml 1097 2277 1093 2265 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="41">Analysis of the presence of CHD8 in the 5&#8242; region of the <italic>CCNE2</italic> and <italic>TYMS</italic> genes by ChIP. (<bold>A</bold>) Crosslinked DNA&#8211;protein complexes from C33A cells were immunoprecipitated with &#945;-CHD8 and &#945;-H3K4me3 (as a positive control). PCR amplification was performed with specific primers of the <italic>CCNE2</italic>, <italic>TYMS</italic> and <italic>ACTB</italic> genes. The center of PCR products relative to the transcription start sites is as follows: +836 for the <italic>CCNE2</italic>, +91 for the <italic>TYMS</italic> and +1294 for the <italic>ACTB</italic> genes. (<bold>B</bold> and <bold>C</bold>) Binding of CHD8 to the <italic>CCNE2</italic> (B) and <italic>TYMS</italic> (C) genes in C33KD2 cells treated or not with Dox for 72 h. (<bold>D</bold>) Distribution of CHD8 over the <italic>CCNE2</italic> gene in C33A cells. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. A diagram of the <italic>CCNE2</italic> gene is also shown. Black boxes correspond to coding exons while grey boxes correspond to the 5&#8242;UTR and 3&#8242;UTR. Transcription start point (+1) and ATG are also indicated. In (B), (C) and (D), immunoprecipitated DNA from three independent experiments was quantified using qPCR and expressed as percentage of the input (B and C) or as fold enrichment respect to the &#8722;11 058 amplicon (D). PI, pre-immune serum.</p></caption>
###xml 2277 2277 2265 2265 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp101f3"/>
###xml 1088 2277 1084 2265 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="41">Analysis of the presence of CHD8 in the 5&#8242; region of the <italic>CCNE2</italic> and <italic>TYMS</italic> genes by ChIP. (<bold>A</bold>) Crosslinked DNA&#8211;protein complexes from C33A cells were immunoprecipitated with &#945;-CHD8 and &#945;-H3K4me3 (as a positive control). PCR amplification was performed with specific primers of the <italic>CCNE2</italic>, <italic>TYMS</italic> and <italic>ACTB</italic> genes. The center of PCR products relative to the transcription start sites is as follows: +836 for the <italic>CCNE2</italic>, +91 for the <italic>TYMS</italic> and +1294 for the <italic>ACTB</italic> genes. (<bold>B</bold> and <bold>C</bold>) Binding of CHD8 to the <italic>CCNE2</italic> (B) and <italic>TYMS</italic> (C) genes in C33KD2 cells treated or not with Dox for 72 h. (<bold>D</bold>) Distribution of CHD8 over the <italic>CCNE2</italic> gene in C33A cells. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. A diagram of the <italic>CCNE2</italic> gene is also shown. Black boxes correspond to coding exons while grey boxes correspond to the 5&#8242;UTR and 3&#8242;UTR. Transcription start point (+1) and ATG are also indicated. In (B), (C) and (D), immunoprecipitated DNA from three independent experiments was quantified using qPCR and expressed as percentage of the input (B and C) or as fold enrichment respect to the &#8722;11 058 amplicon (D). PI, pre-immune serum.</p></caption><graphic xlink:href="gkp101f3"/></fig>
###xml 355 359 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
To verify whether CCNE2 is a direct target of CHD8, a promoter-reporter construct was co-transfected with increasing quantities of a CHD8 expression vector and the expression of the luc reporter gene was determined. As shown in Figure 2D, CHD8 stimulated about 4-fold the activity of the promoter. As a negative control, CHD8 was not able to activate the MMTV promoter either in the absence or in the presence of dexamethasone, its inductor. To further investigate whether CCNE2 and TYMS are direct targets of CHD8 in vivo, we performed chromatin immunoprecipitation (ChIP) assays in C33A cells. Figure 3A shows that CHD8 binds to the 5' region of these genes. Depletion of CHD8 upon Dox addition to C33KD2 cells led to a significant reduction in the amount of immunoprecipitated CCNE2 and TYMS chromatin, which confirms the specificity of the alpha-CHD8 antibodies in our ChIP assays (Figure 3B and C). Next, we decided to investigate the precise location of CHD8 within the CCNE2 gene. As shown in Figure 3D, CHD8 was enriched in the promoter and the transcribed 5' region of the gene. Figure 3.Analysis of the presence of CHD8 in the 5' region of the CCNE2 and TYMS genes by ChIP. (A) Crosslinked DNA-protein complexes from C33A cells were immunoprecipitated with alpha-CHD8 and alpha-H3K4me3 (as a positive control). PCR amplification was performed with specific primers of the CCNE2, TYMS and ACTB genes. The center of PCR products relative to the transcription start sites is as follows: +836 for the CCNE2, +91 for the TYMS and +1294 for the ACTB genes. (B and C) Binding of CHD8 to the CCNE2 (B) and TYMS (C) genes in C33KD2 cells treated or not with Dox for 72 h. (D) Distribution of CHD8 over the CCNE2 gene in C33A cells. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. A diagram of the CCNE2 gene is also shown. Black boxes correspond to coding exons while grey boxes correspond to the 5'UTR and 3'UTR. Transcription start point (+1) and ATG are also indicated. In (B), (C) and (D), immunoprecipitated DNA from three independent experiments was quantified using qPCR and expressed as percentage of the input (B and C) or as fold enrichment respect to the -11 058 amplicon (D). PI, pre-immune serum.
###end p 40
###begin p 41
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 285 290 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 292 296 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 301 305 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 410 415 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 429 433 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 452 456 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 465 466 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 471 472 463 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 497 502 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 511 515 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 577 578 569 570 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 610 615 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 768 773 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
Analysis of the presence of CHD8 in the 5' region of the CCNE2 and TYMS genes by ChIP. (A) Crosslinked DNA-protein complexes from C33A cells were immunoprecipitated with alpha-CHD8 and alpha-H3K4me3 (as a positive control). PCR amplification was performed with specific primers of the CCNE2, TYMS and ACTB genes. The center of PCR products relative to the transcription start sites is as follows: +836 for the CCNE2, +91 for the TYMS and +1294 for the ACTB genes. (B and C) Binding of CHD8 to the CCNE2 (B) and TYMS (C) genes in C33KD2 cells treated or not with Dox for 72 h. (D) Distribution of CHD8 over the CCNE2 gene in C33A cells. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. A diagram of the CCNE2 gene is also shown. Black boxes correspond to coding exons while grey boxes correspond to the 5'UTR and 3'UTR. Transcription start point (+1) and ATG are also indicated. In (B), (C) and (D), immunoprecipitated DNA from three independent experiments was quantified using qPCR and expressed as percentage of the input (B and C) or as fold enrichment respect to the -11 058 amplicon (D). PI, pre-immune serum.
###end p 41
###begin p 42
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 126 134 126 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 547 555 547 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 571 579 571 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 762 767 762 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 803 811 803 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 919 927 919 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 971 976 971 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1070 1078 1070 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1260 1268 1260 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1272 1281 1272 1281 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1305 1310 1305 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1373 1374 1373 1374 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1518 1519 1518 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1664 1669 1664 1669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1674 1678 1674 1678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 1692 1693 1692 1693 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1734 1735 1734 1735 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1973 1974 1965 1966 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1979 1980 1971 1972 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2066 2071 2058 2063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1281 2304 1281 2296 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="43">CHD8 and RNAPII bind to <italic>CCNE2</italic> promoter-proximal region regardless of the cell-cycle phase. (<bold>A</bold>) HeLa cells were synchronized by double thymidine blocking as described in &#8216;Materials and Methods&#8217; section. After the release of the blockade (<italic>t</italic> = 0), samples were taken at the indicated times for flow cytometry analysis. Synchronized cells were taken at the indicated times and levels of <italic>CCNE2</italic> and <italic>ACTB</italic> transcripts (<bold>B</bold>) and CHD8, Cyclin E2 and E2F1 proteins (<bold>C</bold>) were determined by RT&#8211;PCR and immunoblot analysis, respectively. &#945;-E2F1 was used as a control of a typical G1/S- and S-expressed gene. &#945;-Ser2-P-RNAPII antibody (H5) was used as a loading control for immunoblotting experiments. (<bold>D</bold> and <bold>E</bold>) ChIP analysis of the binding of CHD8 (D) and total RNAPII (N20 antibody) (E) to the <italic>CCNE2</italic> gene in different cell-cycle phases. Numbers correspond to the center nucleotide of the real-time PCR product relative to the transcription start site. Data are the average of 12 qPCR determinations from two independent experiments.</p>
###xml 1281 2304 1281 2296 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="43">CHD8 and RNAPII bind to <italic>CCNE2</italic> promoter-proximal region regardless of the cell-cycle phase. (<bold>A</bold>) HeLa cells were synchronized by double thymidine blocking as described in &#8216;Materials and Methods&#8217; section. After the release of the blockade (<italic>t</italic> = 0), samples were taken at the indicated times for flow cytometry analysis. Synchronized cells were taken at the indicated times and levels of <italic>CCNE2</italic> and <italic>ACTB</italic> transcripts (<bold>B</bold>) and CHD8, Cyclin E2 and E2F1 proteins (<bold>C</bold>) were determined by RT&#8211;PCR and immunoblot analysis, respectively. &#945;-E2F1 was used as a control of a typical G1/S- and S-expressed gene. &#945;-Ser2-P-RNAPII antibody (H5) was used as a loading control for immunoblotting experiments. (<bold>D</bold> and <bold>E</bold>) ChIP analysis of the binding of CHD8 (D) and total RNAPII (N20 antibody) (E) to the <italic>CCNE2</italic> gene in different cell-cycle phases. Numbers correspond to the center nucleotide of the real-time PCR product relative to the transcription start site. Data are the average of 12 qPCR determinations from two independent experiments.</p></caption>
###xml 2304 2304 2296 2296 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp101f4"/>
###xml 1272 2304 1272 2296 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="43">CHD8 and RNAPII bind to <italic>CCNE2</italic> promoter-proximal region regardless of the cell-cycle phase. (<bold>A</bold>) HeLa cells were synchronized by double thymidine blocking as described in &#8216;Materials and Methods&#8217; section. After the release of the blockade (<italic>t</italic> = 0), samples were taken at the indicated times for flow cytometry analysis. Synchronized cells were taken at the indicated times and levels of <italic>CCNE2</italic> and <italic>ACTB</italic> transcripts (<bold>B</bold>) and CHD8, Cyclin E2 and E2F1 proteins (<bold>C</bold>) were determined by RT&#8211;PCR and immunoblot analysis, respectively. &#945;-E2F1 was used as a control of a typical G1/S- and S-expressed gene. &#945;-Ser2-P-RNAPII antibody (H5) was used as a loading control for immunoblotting experiments. (<bold>D</bold> and <bold>E</bold>) ChIP analysis of the binding of CHD8 (D) and total RNAPII (N20 antibody) (E) to the <italic>CCNE2</italic> gene in different cell-cycle phases. Numbers correspond to the center nucleotide of the real-time PCR product relative to the transcription start site. Data are the average of 12 qPCR determinations from two independent experiments.</p></caption><graphic xlink:href="gkp101f4"/></fig>
CCNE2 is an E2F-dependent gene transcriptionally active only during the G1/S and S phase fractions of the cell cycle (41,42) (Figure 4B and C). Thus, we wondered whether the association of CHD8 with the CCNE2 gene was cell-cycle-regulated. For that, we synchronized HeLa cells in G1/S by double thymidine blocking and performed ChIP experiments at different cell-cycle stages obtained by differential timed release in normal media. Given our interest in the G1/S transition, we used cell populations synchronized at early G1, late G1, G1/S and S (Figure 4A). As shown in Figure 4B and C, while the levels of CHD8 were not affected by the cell cycle, CCNE2 was only expressed at the G1/S and S fractions. ChIP experiments evidenced that CHD8 remains bound to the CCNE2 gene during the entire cell cycle (Figure 4D). Interestingly, a constitutive RNAPII occupancy at the CCNE2 promoter-proximal region was also observed (Figure 4E), suggesting that RNAPII is paused at the CCNE2 gene during both early and late G1 fractions, when the gene is not transcriptionally active (Figure 4B and C). However, a significant increase of RNAPII occupancy in the promoter and in body of the gene was observed at the G1/S transition coincident with the activation of the gene (Figure 4E). Figure 4.CHD8 and RNAPII bind to CCNE2 promoter-proximal region regardless of the cell-cycle phase. (A) HeLa cells were synchronized by double thymidine blocking as described in 'Materials and Methods' section. After the release of the blockade (t = 0), samples were taken at the indicated times for flow cytometry analysis. Synchronized cells were taken at the indicated times and levels of CCNE2 and ACTB transcripts (B) and CHD8, Cyclin E2 and E2F1 proteins (C) were determined by RT-PCR and immunoblot analysis, respectively. alpha-E2F1 was used as a control of a typical G1/S- and S-expressed gene. alpha-Ser2-P-RNAPII antibody (H5) was used as a loading control for immunoblotting experiments. (D and E) ChIP analysis of the binding of CHD8 (D) and total RNAPII (N20 antibody) (E) to the CCNE2 gene in different cell-cycle phases. Numbers correspond to the center nucleotide of the real-time PCR product relative to the transcription start site. Data are the average of 12 qPCR determinations from two independent experiments.
###end p 42
###begin p 43
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 92 93 92 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 411 412 411 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 453 454 453 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 692 693 684 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 698 699 690 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 785 790 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
CHD8 and RNAPII bind to CCNE2 promoter-proximal region regardless of the cell-cycle phase. (A) HeLa cells were synchronized by double thymidine blocking as described in 'Materials and Methods' section. After the release of the blockade (t = 0), samples were taken at the indicated times for flow cytometry analysis. Synchronized cells were taken at the indicated times and levels of CCNE2 and ACTB transcripts (B) and CHD8, Cyclin E2 and E2F1 proteins (C) were determined by RT-PCR and immunoblot analysis, respectively. alpha-E2F1 was used as a control of a typical G1/S- and S-expressed gene. alpha-Ser2-P-RNAPII antibody (H5) was used as a loading control for immunoblotting experiments. (D and E) ChIP analysis of the binding of CHD8 (D) and total RNAPII (N20 antibody) (E) to the CCNE2 gene in different cell-cycle phases. Numbers correspond to the center nucleotide of the real-time PCR product relative to the transcription start site. Data are the average of 12 qPCR determinations from two independent experiments.
###end p 43
###begin title 44
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The tandem chromodomains of CHD8 bind H3K4me2 in vitro
###end title 44
###begin p 45
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 389 397 389 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 474 482 474 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 503 519 503 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 796 804 796 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1145 1147 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1680 1682 1680 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1785 1792 1785 1792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1958 1963 1958 1963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 2061 2066 2061 2066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 2141 2149 2141 2149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2218 2223 2218 2223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 2230 2239 2230 2239 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 2289 2297 2289 2297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2300 2301 2300 2301 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2362 2363 2362 2363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2791 2792 2787 2788 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2864 2869 2860 2865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 2239 3182 2239 3178 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="46">The tandem chromodomains of CHD8 bind to H3K4me2, <italic>in vitro</italic>. (<bold>A</bold>) Schematic of the CHD8 fragments used for binding studies. (<bold>B</bold>) Purified GST, GST-CD1, GST-CD2, GST-CD1+CD2, GST-CD1+mutCD2 and GST-mutCD1+CD2 proteins were incubated with different biotinylated histone H3 N-terminal peptides, such as unmodified (H3), Lys 4-di-methylated (H3K4me2), Lys 4-tri-methylated (H3K4me3) or Lys 9-di-methylated (H3K9me2). Bound fractions from the binding reactions were analyzed by western blotting using &#945;-GST antibody. A representative experiment is shown. (<bold>C</bold>) Analysis of the levels of H3K4me2 and H3K4me3 in the 5&#8242; region of the <italic>CCNE2</italic> gene by ChIP in C33KD2 cells treated or not with Dox during 72 h. Immunoprecipitated DNA from three independent experiments was quantified using qPCR. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. Data are expressed as percentage of the input.</p>
###xml 2239 3182 2239 3178 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="46">The tandem chromodomains of CHD8 bind to H3K4me2, <italic>in vitro</italic>. (<bold>A</bold>) Schematic of the CHD8 fragments used for binding studies. (<bold>B</bold>) Purified GST, GST-CD1, GST-CD2, GST-CD1+CD2, GST-CD1+mutCD2 and GST-mutCD1+CD2 proteins were incubated with different biotinylated histone H3 N-terminal peptides, such as unmodified (H3), Lys 4-di-methylated (H3K4me2), Lys 4-tri-methylated (H3K4me3) or Lys 9-di-methylated (H3K9me2). Bound fractions from the binding reactions were analyzed by western blotting using &#945;-GST antibody. A representative experiment is shown. (<bold>C</bold>) Analysis of the levels of H3K4me2 and H3K4me3 in the 5&#8242; region of the <italic>CCNE2</italic> gene by ChIP in C33KD2 cells treated or not with Dox during 72 h. Immunoprecipitated DNA from three independent experiments was quantified using qPCR. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. Data are expressed as percentage of the input.</p></caption>
###xml 3182 3182 3178 3178 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp101f5"/>
###xml 2230 3182 2230 3178 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="46">The tandem chromodomains of CHD8 bind to H3K4me2, <italic>in vitro</italic>. (<bold>A</bold>) Schematic of the CHD8 fragments used for binding studies. (<bold>B</bold>) Purified GST, GST-CD1, GST-CD2, GST-CD1+CD2, GST-CD1+mutCD2 and GST-mutCD1+CD2 proteins were incubated with different biotinylated histone H3 N-terminal peptides, such as unmodified (H3), Lys 4-di-methylated (H3K4me2), Lys 4-tri-methylated (H3K4me3) or Lys 9-di-methylated (H3K9me2). Bound fractions from the binding reactions were analyzed by western blotting using &#945;-GST antibody. A representative experiment is shown. (<bold>C</bold>) Analysis of the levels of H3K4me2 and H3K4me3 in the 5&#8242; region of the <italic>CCNE2</italic> gene by ChIP in C33KD2 cells treated or not with Dox during 72 h. Immunoprecipitated DNA from three independent experiments was quantified using qPCR. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. Data are expressed as percentage of the input.</p></caption><graphic xlink:href="gkp101f5"/></fig>
###xml 503 519 <span type="species:ncbi:562">Escherichia coli</span>
###xml 1563 1568 <span type="species:ncbi:9606">human</span>
CHD8 contains two chromodomains (CDs) within its amino-terminal half. Chromodomains have been shown to mediate interactions of chromatin factors with methylated lysines of the histone tails. In fact, the similar CHD1 tandem chromodomains bind histone H3 tri-methylated in lysine 4 (43,44). Therefore, we decided to investigate whether the tandem CDs of CHD8 directly bind methylated H3K4, in vitro. For that, its first (CD1), second (CD2) or tandem chromodomains (CD1+CD2) (Figure 5A) were expressed in Escherichia coli as GST-fusion proteins. Recombinant purified proteins were incubated with biotinylated peptides corresponding to the first 21 amino acids of histone H3, either unmodified or modified by methylation in lysine 4 (di-methylated or tri-methylated) or in lysine 9 (di-methylated). Figure 5B shows that while CD1 was unable to interact with any histone H3 peptide, CD2 bound the four peptides without significant preference. More importantly, the tandem chromodomains mostly interacted with the H3K4me2 peptide. Single chromodomain proteins bind to methylated lysines by interaction with several aromatic residues (aromatic cage) (28). Thus, mutation of the conserved aromatic residues W751 and Y756 of CD2 completely abolished the binding activity of the tandem chromodomains. However, a triple mutation of the conserved aromatic residues (Y672L, Y675L, Y677L) of CD1 does not affect the binding. Therefore, our data suggest that CD1 contribution to the binding specificity does not require its aromatic cage. This is consistent with data from the human CHD1 protein, where the H3-methylated peptide interacts with an acidic surface bridging chromodomains 1 and 2 (44). These data suggest a possible role of H3K4me2 in recruiting CHD8 to the chromatin. However, further in vivo experiments are required to confirm this hypothesis. Then we decided to investigate whether the level of CHD8 affects the degree of methylation of histone H3 in the CCNE2 gene. ChIP experiments demonstrated that histone H3 is di- and tri-methylated in lysine 4 in the CCNE2 promoter and 5' transcribed region, irrespectively of the levels of CHD8 (Figure 5C), indicating that CHD8 is not required for H3K4 methylation at the CCNE2 gene. Figure 5.The tandem chromodomains of CHD8 bind to H3K4me2, in vitro. (A) Schematic of the CHD8 fragments used for binding studies. (B) Purified GST, GST-CD1, GST-CD2, GST-CD1+CD2, GST-CD1+mutCD2 and GST-mutCD1+CD2 proteins were incubated with different biotinylated histone H3 N-terminal peptides, such as unmodified (H3), Lys 4-di-methylated (H3K4me2), Lys 4-tri-methylated (H3K4me3) or Lys 9-di-methylated (H3K9me2). Bound fractions from the binding reactions were analyzed by western blotting using alpha-GST antibody. A representative experiment is shown. (C) Analysis of the levels of H3K4me2 and H3K4me3 in the 5' region of the CCNE2 gene by ChIP in C33KD2 cells treated or not with Dox during 72 h. Immunoprecipitated DNA from three independent experiments was quantified using qPCR. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. Data are expressed as percentage of the input.
###end p 45
###begin p 46
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 61 62 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 552 553 548 549 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 625 630 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
The tandem chromodomains of CHD8 bind to H3K4me2, in vitro. (A) Schematic of the CHD8 fragments used for binding studies. (B) Purified GST, GST-CD1, GST-CD2, GST-CD1+CD2, GST-CD1+mutCD2 and GST-mutCD1+CD2 proteins were incubated with different biotinylated histone H3 N-terminal peptides, such as unmodified (H3), Lys 4-di-methylated (H3K4me2), Lys 4-tri-methylated (H3K4me3) or Lys 9-di-methylated (H3K9me2). Bound fractions from the binding reactions were analyzed by western blotting using alpha-GST antibody. A representative experiment is shown. (C) Analysis of the levels of H3K4me2 and H3K4me3 in the 5' region of the CCNE2 gene by ChIP in C33KD2 cells treated or not with Dox during 72 h. Immunoprecipitated DNA from three independent experiments was quantified using qPCR. Numbers correspond to the center nucleotide of the real time PCR product relative to the transcription start site. Data are expressed as percentage of the input.
###end p 46
###begin title 47
CHD8 associates with phosphorylated RNAPII
###end title 47
###begin p 48
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 806 814 806 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 939 947 939 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 951 960 951 960 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 1000 1001 1000 1001 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1032 1039 1032 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1246 1247 1242 1243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1252 1253 1248 1249 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 960 1643 960 1639 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="49">CHD8 interacts with elongating RNAPII. (<bold>A</bold>) CHD8 associates with RNAPIIo <italic>in vivo</italic>. Immunoblot analysis of C33A total extract (input) and fractions immunoprecipitated with &#945;-CHD8 or nonspecific antiserum (mock). Antibodies used for immunoblot are indicated on the left in each panel. (<bold>B</bold> and <bold>C</bold>) CHD8-depleted cells are hypersensitive to transcription elongation inhibitors. C33KD2 cells were grown with or without Dox and with or without flavopiridol (B) or DRB (C) at the indicated concentrations. Total cell numbers were determined after 5 days under the indicated conditions. Percentage of growth inhibition in the presence of either of flavopiridol (B) or DRB (C) is represented.</p>
###xml 960 1643 960 1639 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="49">CHD8 interacts with elongating RNAPII. (<bold>A</bold>) CHD8 associates with RNAPIIo <italic>in vivo</italic>. Immunoblot analysis of C33A total extract (input) and fractions immunoprecipitated with &#945;-CHD8 or nonspecific antiserum (mock). Antibodies used for immunoblot are indicated on the left in each panel. (<bold>B</bold> and <bold>C</bold>) CHD8-depleted cells are hypersensitive to transcription elongation inhibitors. C33KD2 cells were grown with or without Dox and with or without flavopiridol (B) or DRB (C) at the indicated concentrations. Total cell numbers were determined after 5 days under the indicated conditions. Percentage of growth inhibition in the presence of either of flavopiridol (B) or DRB (C) is represented.</p></caption>
###xml 1643 1643 1639 1639 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp101f6"/>
###xml 951 1643 951 1639 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="49">CHD8 interacts with elongating RNAPII. (<bold>A</bold>) CHD8 associates with RNAPIIo <italic>in vivo</italic>. Immunoblot analysis of C33A total extract (input) and fractions immunoprecipitated with &#945;-CHD8 or nonspecific antiserum (mock). Antibodies used for immunoblot are indicated on the left in each panel. (<bold>B</bold> and <bold>C</bold>) CHD8-depleted cells are hypersensitive to transcription elongation inhibitors. C33KD2 cells were grown with or without Dox and with or without flavopiridol (B) or DRB (C) at the indicated concentrations. Total cell numbers were determined after 5 days under the indicated conditions. Percentage of growth inhibition in the presence of either of flavopiridol (B) or DRB (C) is represented.</p></caption><graphic xlink:href="gkp101f6"/></fig>
As a first step in the characterization of the mechanism by which CHD8 controls gene expression we investigated whether CHD8 interacts with RNAPII. When recruited to promoters, the CTD of the largest subunit of RNAPII is unphosphorylated (RNAPIIa). After promoter clearance and during early stages of elongation, firstly serine 5 (Ser5) and subsequently serine 2 (Ser2) are phosphorylated (Ser5-P and Ser2-P) (RNAPIIo) (45). The 8WG16 antibody recognizes mostly unmodified CTD repeats and some intermediate phosphorylated forms (46), while antibodies H14 and CTD4H8 recognize Ser5-P CTD and antibody H5 recognizes Ser2-P CTD repeats. In contrast, antibody N20 recognizes all RNAPII forms. Interestingly, CHD8 co-immunoprecipitated with hyperphosphorylated RNAPIIo complexes enriched for Ser5-P and Ser2-P (Figure 6A). However, CHD8 did not co-immunoprecipitate with the transcription elongation factor SPT5 or with the HMG protein BRAF35 (Figure 6A). Figure 6.CHD8 interacts with elongating RNAPII. (A) CHD8 associates with RNAPIIo in vivo. Immunoblot analysis of C33A total extract (input) and fractions immunoprecipitated with alpha-CHD8 or nonspecific antiserum (mock). Antibodies used for immunoblot are indicated on the left in each panel. (B and C) CHD8-depleted cells are hypersensitive to transcription elongation inhibitors. C33KD2 cells were grown with or without Dox and with or without flavopiridol (B) or DRB (C) at the indicated concentrations. Total cell numbers were determined after 5 days under the indicated conditions. Percentage of growth inhibition in the presence of either of flavopiridol (B) or DRB (C) is represented.
###end p 48
###begin p 49
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 286 287 282 283 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 292 293 288 289 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
CHD8 interacts with elongating RNAPII. (A) CHD8 associates with RNAPIIo in vivo. Immunoblot analysis of C33A total extract (input) and fractions immunoprecipitated with alpha-CHD8 or nonspecific antiserum (mock). Antibodies used for immunoblot are indicated on the left in each panel. (B and C) CHD8-depleted cells are hypersensitive to transcription elongation inhibitors. C33KD2 cells were grown with or without Dox and with or without flavopiridol (B) or DRB (C) at the indicated concentrations. Total cell numbers were determined after 5 days under the indicated conditions. Percentage of growth inhibition in the presence of either of flavopiridol (B) or DRB (C) is represented.
###end p 49
###begin p 50
###xml 547 548 544 545 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 671 676 668 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47 B48 B49">47&#8211;49</xref>
###xml 679 687 676 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
The fact that CHD8 associates with the elongating forms of RNAPII suggested that CHD8 might have a role in elongation. To support this hypothesis we asked whether CHD8-depleted cells were hypersensitive to inhibitors of transcription elongation. We reasoned that if elongation of some genes is altered in CHD8-depleted cells, a partial inhibition of elongation should enhance the effect of CHD8 depletion provoking a synthetic phenotype. Indeed, CHD8-depleted cells were hypersensitive to low concentrations of flavopiridol or 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole (DRB), two drugs that impair elongation by inhibiting CDK9, a component of the P-TEFb complex (47-49) (Figure 6B and C).
###end p 50
###begin title 51
DISCUSSION
###end title 51
###begin p 52
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 325 332 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 717 722 717 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50 B51 B52">50&#8211;52</xref>
###xml 863 868 863 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 1035 1040 1035 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53 B54 B55">53&#8211;55</xref>
###xml 1201 1203 1201 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
Here we show that CCNE2 is a direct target of CHD8. A number of results support this conclusion. First, CHD8-depleted cells present decreased levels of the CCNE2 transcript and its protein. Second, CHD8 transactivates the CCNE2 promoter in transient transfection experiments. And third, CHD8 binds directly to the CCNE2 gene in vivo. We also provide several lines of evidence suggesting that CHD8 plays a positive role in the first steps of RNAPII elongation. First, CHD8 co-immunoprecipitates with RNAPII phosphorylated in serines 5 and 2 of its CTD, but not with non-phosphorylated RNAPII. Similarly to CHD8, other typical elongating factors such as Spt6, DSIF and the PAF complex associate with elongating RNAPII (50-52). Second, ChIP experiments demonstrate that CHD8 binds not only to the promoter but also to the promoter-proximal transcribed region of the CCNE2 gene. In the same way, but unlike initiation factors, elongation factors such as DSIF, Spt6, TREX and PAF complexes associate with the coding region of active genes (53-55). Third, CHD8-depleted cells are hypersensitive to flavopiridol and DRB, drugs that provoke RNAPII arrest by inhibiting RNAPII CTD phosphorylation at serine 2 (56,57). The fact that CHD8-depleted cells are hypersensitive to both inhibitors suggests that CHD8 acts in the same process that is being inhibited by the drugs. Although these experiments suggest a role for CHD8 during the first steps of elongation, we can not rule out an additional role for this factor in the formation of the pre-initiation complex.
###end p 52
###begin p 53
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 271 281 271 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kismet</italic>
###xml 344 352 344 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Polycomb</italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 605 608 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kis</italic>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 852 855 852 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kis</italic>
###xml 950 958 950 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1022 1032 1022 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1387 1391 1387 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 271 281 <span type="species:ncbi:7227">Drosophila</span>
###xml 1022 1032 <span type="species:ncbi:7227">Drosophila</span>
As defined by Flaus et al., the ATPase CHD8 belongs to the CHD7 subfamily of the SNF2 family (5). In addition to CHD8, other three proteins belong to this subfamily in mammals: CHD6, CHD7 and CHD9. In contrast, only one protein called Kismet belongs to this subfamily in Drosophila. The kismet gene was originally identified as a suppressor of Polycomb mutations and, therefore, belongs to the trithorax group of genes (58). Kismet has been shown to play important roles in both segmentation and determination of body segment identity (59), and was found to co-localize with almost all RNAPII sites (60). kis mutants display a dramatic reduction in the levels of both CTD-Ser2 phosphorylated RNAPII and the elongation factors dSPT6 and dCHD1 on polytene chromosomes, suggesting that Kismet is required for transcription elongation (60). In contrast to kis mutations, CHD8 depletion does not generally reduce the levels of Ser2-phosphorylated RNAPII (Figure 1). One possibility is that the function that Kismet performs in Drosophila is carried out in mammals by several members of the subfamily (CHD6 to CHD9). This would explain why the depletion of only one member of the subfamily does not have a general effect, but a gene-specific effect. This is consistent with our whole genome expression analysis, as only a small number of genes were found to be misregulated upon knocking down CHD8.
###end p 53
###begin p 54
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 967 972 967 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 1152 1155 1152 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fkh</italic>
While preparing the revised version of this manuscript it has been reported that loss of Kismet function leads to a reduction in the level of the H3K4 methyl transferases TRX and ASH1 on polytene chromosomes (61). In agreement with the hypothesis that CHD8 and Kismet are functional orthologs, it has been shown that CHD8 co-purifies with components of the MLL1 (mixed-lineage leukemia) complex (31,62), the mammalian TRX homolog. Moreover, and consistently with what we describe for CHD8, MLL1 has been found to interact with elongating RNAPII and bind to the promoters and 5' transcribed regions of the genes. However, while MLL1 mostly associates with transcriptionally active genes, CHD8 binds to the CCNE2 gene under conditions of both activation and repression. Furthermore, depletion of CHD8 does not affect the levels of H3K4me2 or H3K4me3, suggesting that CHD8 does not cooperate with the MLL1 complex for histone H3K4 methylation. Interestingly, Srinivasan et al. (61) have also shown that, despite the reduced recruitment of TRX and ASH1, the loss of Kismet has no effect on the level of H3K4 methylation on polytene chromosomes or over the fkh gene. The connection between H3K4 histone methyl transferases and Kismet/CHD8 proteins requires further investigation.
###end p 54
###begin p 55
###xml 203 213 203 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 247 255 247 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 572 577 572 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 708 716 708 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B64">64</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B65">65</xref>
###xml 914 919 914 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 984 985 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1293 1298 1293 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 203 213 <span type="species:ncbi:7227">Drosophila</span>
The way CHD8 is recruited to its target genes remains unknown. One possibility is that some specific histone modifications contribute to the recruitment of CHD8. Here we demonstrate that, in contrast to Drosophila Kismet (61), CHD8 directly binds in vitro to H3K4me2 through its tandem chromodomains. Consistently with our results, Yuan et al. recently used fractions enriched for CHD8 to demonstrate its direct or indirect association with di- and tri-methylated lysine 4 of histone H3 amino-terminal peptides (63). We also found that CHD8 is constitutively bound to the CCNE2 gene, even during G1, when the gene is not active. This is also consistent with the fact that CHD8 interacts with histone H3K4me2 in vitro, since H3K4me3 correlates with actively transcribed genes while H3K4me2 can be present on poised, inactive genes (64,65). Interestingly we also found significant levels of RNAPII associated to the CCNE2 gene under conditions of repression. Promoter-proximal pausing (1) is a widespread phenomenon that takes place in many genes, where RNAPII pauses in the 5' region of transcription units and only progresses into productive elongation upon stimulation by appropriate signals. Paused RNAPII is phosphorylated at serine 5 of its CTD. The association of CHD8 with the repressed CCNE2 gene and the fact that it interacts with Ser5-P-RNAPII suggest that CHD8 might be recruited to genes having paused RNAPII.
###end p 55
###begin p 56
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 261 263 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 348 353 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 358 362 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYMS</italic>
###xml 440 442 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 506 511 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE1</italic>
###xml 513 518 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNA2</italic>
###xml 520 523 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK1</italic>
###xml 525 529 522 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCNA</italic>
###xml 533 537 530 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 699 704 696 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE1</italic>
###xml 709 712 706 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK1</italic>
###xml 147 152 <span type="species:ncbi:9606">human</span>
CHD8 may also be recruited to its targets by interaction with specific transcription factors. In fact, it has been shown that CHD8 associates with human staf/ZNF143, a zinc finger protein that controls the expression of the U6 gene (63), and with beta-catenin (31). In this respect we found that, although CHD8 is required for normal expression of CCNE2 and TYMS, two G1/S-specific genes which are targets of the E2F1 transcription factor (41), the expression of other typical E2F1-dependent genes such as CCNE1, CCNA2, TK1, PCNA or E2F1 itself did not change significantly under conditions of CHD8 depletion. Nonetheless and interestingly, we have verified the presence of CHD8 in the 5' region of CCNE1 and TK1 by ChIP experiments (data not shown). Furthermore, in transient transfection experiments CHD8 was also able to activate the expression of a minimal promoter containing an E2F1 synthetic binding site (data not shown). One possibility is that E2F1 could recruit CHD8 to all E2F1-dependent genes but that only those genes with a specific chromatin structure at the 5' region require CHD8 for normal elongation. Therefore, we suggest that the specificity of CHD8 for a subset of genes may involve its interaction with specific transcription factors, specific histone modifications and the phosphorylation status of RNAPII.
###end p 56
###begin title 57
SUPPLEMENTARY DATA
###end title 57
###begin p 58
 are available at NAR Online.
###end p 58
###begin title 59
FUNDING
###end title 59
###begin p 60
Ministerio de Educacion y Ciencia [BFU2005-01047, CSD2006-00049]; Junta de Andalucia [P06-CVI-01400]. Funding for open access charge: Spanish Ministerio de Educacion y Ciencia.
###end p 60
###begin p 61
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplementary Data]
###end title 63
###begin title 64
ACKNOWLEDGEMENTS
###end title 64
###begin p 65
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHD8</italic>
###xml 60 65 <span type="species:ncbi:9606">Human</span>
We thank Kazusa DNA Research Institute and Chinese National Human Genome Center for providing partial CHD8 cDNA clones. We thank Drs C. Muchardt, J.R. Nevins, H. Clevers and M. van de Wetering for providing different plasmids and cell lines, A. Aguilera for critical reading of the manuscript and Sanofi-Aventis for the gift of flavopiridol.
###end p 65
###begin title 66
REFERENCES
###end title 66
###begin article-title 67
Breaking barriers to transcription elongation
###end article-title 67
###begin article-title 68
The role of chromatin during transcription
###end article-title 68
###begin article-title 69
ATP-dependent chromatin remodeling
###end article-title 69
###begin article-title 70
###xml 68 72 <span type="species:ncbi:8233">tuna</span>
Mechanisms for ATP-dependent chromatin remodelling: farewell to the tuna-can octamer?
###end article-title 70
###begin article-title 71
Identification of multiple distinct Snf2 subfamilies with conserved structural motifs
###end article-title 71
###begin article-title 72
Role of nucleosome remodeling factor NURF in transcriptional activation of chromatin
###end article-title 72
###begin article-title 73
Chromatin remodelling at the PHO8 promoter requires SWI-SNF and SAGA at a step subsequent to activator binding
###end article-title 73
###begin article-title 74
###xml 63 87 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Ssn6-Tup1 requires the ISW2 complex to position nucleosomes in Saccharomyces cerevisiae
###end article-title 74
###begin article-title 75
Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation
###end article-title 75
###begin article-title 76
Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor gamma nuclear hormone receptor
###end article-title 76
###begin article-title 77
Coordination of PIC assembly and chromatin remodeling during differentiation-induced gene activation
###end article-title 77
###begin article-title 78
Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter
###end article-title 78
###begin article-title 79
Chromatin remodeling by RNA polymerases
###end article-title 79
###begin article-title 80
Nature of the nucleosomal barrier to RNA polymerase II
###end article-title 80
###begin article-title 81
de FACTo nucleosome dynamics
###end article-title 81
###begin article-title 82
Synergistic functions of SII and p300 in productive activator-dependent transcription of chromatin templates
###end article-title 82
###begin article-title 83
Activator-dependent regulation of transcriptional pausing on nucleosomal templates
###end article-title 83
###begin article-title 84
RSC exploits histone acetylation to abrogate the nucleosomal block to RNA polymerase II elongation
###end article-title 84
###begin article-title 85
###xml 57 67 <span type="species:ncbi:7227">Drosophila</span>
CHD1 is concentrated in interbands and puffed regions of Drosophila polytene chromosomes
###end article-title 85
###begin article-title 86
Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes
###end article-title 86
###begin article-title 87
Characterization of the CHD family of proteins
###end article-title 87
###begin article-title 88
###xml 37 61 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II
###end article-title 88
###begin article-title 89
CHD1 interacts with SSRP1 and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin
###end article-title 89
###begin article-title 90
###xml 40 64 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
RNA polymerase II elongation factors of Saccharomyces cerevisiae: a targeted proteomics approach
###end article-title 90
###begin article-title 91
CHD1 motor protein is required for deposition of histone variant H3.3 into chromatin in vivo
###end article-title 91
###begin article-title 92
The CHD remodeling factor Hrp1 stimulates CENP-A loading to centromeres
###end article-title 92
###begin article-title 93
The Chd family of chromatin remodelers
###end article-title 93
###begin article-title 94
The many colours of chromodomains
###end article-title 94
###begin article-title 95
CTCF-dependent chromatin insulator is linked to epigenetic remodeling
###end article-title 95
###begin article-title 96
###xml 21 26 <span type="species:ncbi:9606">human</span>
CHD8 associates with human Staf and contributes to efficient U6 RNA polymerase III transcription
###end article-title 96
###begin article-title 97
CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes
###end article-title 97
###begin article-title 98
Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha)
###end article-title 98
###begin article-title 99
E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases
###end article-title 99
###begin article-title 100
Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector
###end article-title 100
###begin article-title 101
A system for stable expression of short interfering RNAs in mammalian cells
###end article-title 101
###begin article-title 102
Novel activities of Mafb underlie its dual role in hindbrain segmentation and regional specification
###end article-title 102
###begin article-title 103
Regulation of the cyclin E gene by transcription factor E2F1
###end article-title 103
###begin article-title 104
Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation
###end article-title 104
###begin article-title 105
###xml 18 23 <span type="species:ncbi:9606">human</span>
Components of the human SWI/SNF complex are enriched in active chromatin and are associated with the nuclear matrix
###end article-title 105
###begin article-title 106
###xml 33 57 33 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Saccharomyces cerevisiae</italic>
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 33 57 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm
###end article-title 106
###begin article-title 107
E2F target genes: unraveling the biology
###end article-title 107
###begin article-title 108
###xml 19 24 <span type="species:ncbi:9606">human</span>
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins
###end article-title 108
###begin article-title 109
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 14 19 <span type="species:ncbi:4932">yeast</span>
Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains
###end article-title 109
###begin article-title 110
Double chromodomains cooperate to recognize the methylated histone H3 tail
###end article-title 110
###begin article-title 111
Elongation by RNA polymerase II: the short and long of it
###end article-title 111
###begin article-title 112
Splicing speckles are not reservoirs of RNA polymerase II, but contain an inactive form, phosphorylated on serine2 residues of the C-terminal domain
###end article-title 112
###begin article-title 113
###xml 64 74 <span type="species:ncbi:7227">Drosophila</span>
Identification of a cyclin subunit required for the function of Drosophila P-TEFb
###end article-title 113
###begin article-title 114
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo
###end article-title 114
###begin article-title 115
Controlling the elongation phase of transcription with P-TEFb
###end article-title 115
###begin article-title 116
###xml 108 113 <span type="species:ncbi:9606">human</span>
DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs
###end article-title 116
###begin article-title 117
###xml 49 73 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Paf1p, an RNA polymerase II-associated factor in Saccharomyces cerevisiae, may have both positive and negative roles in transcription
###end article-title 117
###begin article-title 118
The Spt6 SH2 domain binds Ser2-P RNAPII to direct Iws1-dependent mRNA splicing and export
###end article-title 118
###begin article-title 119
Transitions in RNA polymerase II elongation complexes at the 3' ends of genes
###end article-title 119
###begin article-title 120
Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo
###end article-title 120
###begin article-title 121
Transcription elongation factors repress transcription initiation from cryptic sites
###end article-title 121
###begin article-title 122
RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes
###end article-title 122
###begin article-title 123
###xml 93 98 <span type="species:ncbi:10090">mouse</span>
Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells
###end article-title 123
###begin article-title 124
###xml 69 79 69 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 69 79 <span type="species:ncbi:7227">Drosophila</span>
Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila
###end article-title 124
###begin article-title 125
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 4 14 <span type="species:ncbi:7227">Drosophila</span>
The Drosophila kismet gene is related to chromatin-remodeling factors and is required for both segmentation and segment identity
###end article-title 125
###begin article-title 126
###xml 4 14 <span type="species:ncbi:7227">Drosophila</span>
The Drosophila trithorax group protein Kismet facilitates an early step in transcriptional elongation by RNA Polymerase II
###end article-title 126
###begin article-title 127
###xml 0 10 <span type="species:ncbi:7227">Drosophila</span>
Drosophila Kismet regulates histone H3 lysine 27 methylation and early elongation by RNA polymerase II
###end article-title 127
###begin article-title 128
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF
###end article-title 128
###begin article-title 129
###xml 21 26 <span type="species:ncbi:9606">human</span>
CHD8 associates with human Staf and contributes to efficient U6 RNA polymerase III transcription
###end article-title 129
###begin article-title 130
Histone H3 lysine 4 methylation patterns in higher eukaryotic genes
###end article-title 130
###begin article-title 131
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Genomic maps and comparative analysis of histone modifications in human and mouse
###end article-title 131

